User Image Cart Icon 0 Search Image

Amylin

  1. Molecular physiology of amylin
  2. The role of amylin in the control of energy homeostasis
  3. Amylin: history and overview
  4. Dose-response for glucagonostatic effect of amylin in rats
  5. Polymorphic fibrillar assembly of human amylin
  6. Amylin: a novel action in the brain to reduce body weight
  7. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin
  8. Amylin decreases meal size in rats
  9. Clinical implications of amylin and amylin deficiency
  10. Amylin agonists: a novel approach in the treatment of diabetes
  11. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients
  12. Amylin, food intake, and obesity
  13. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin
  14. Degradation of amylin by insulin-degrading enzyme
  15. In vitro autoradiographic localization of amylin binding sites in rat brain
  16. The role of amylin in the physiology of glycemic control
  17. Anorexia following the intrahypothalamic administration of amylin
  18. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans
  19. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin
  20. Permeability of the blood-brain barrier to amylin
  21. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus
  22. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
  23. High affinity amylin binding sites in rat brain.
  24. Stable and metastable states of human amylin in solution
  25. Mechanisms of amylin/leptin synergy in rodent models
  26. Roles of amylin in diabetes and in regulation of nutrient load.
  27. Expression of the rat amylin (IAPP/DAP) gene.
  28. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin
  29. Structure and biology of amylin
  30. Full-length rat amylin forms fibrils following substitution of single residues from human amylin
  31. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus.
  32. The physiology of amylin and insulin
  33. Pore Formation by the Cytotoxic Islet Amyloid Peptide Amylin (∗)
  34. Atomic structure of the cross‐β spine of islet amyloid polypeptide (amylin)
  35. Amylin decreases food intake in mice
  36. Central amylin expression and its induction in rat dams
  37. Pancreatic amylin as a centrally acting satiating hormone
  38. The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin
  39. Amyloid fibril formation from full-length and fragments of amylin
  40. Dynamic α-helix structure of micelle-bound human amylin
  41. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin
  42. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans
  43. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment.
  44. Amylin receptors: molecular composition and pharmacology
  45. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease
  46. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
  47. Differential permeability of the blood–brain barrier to two pancreatic peptides: insulin and amylin
  48. Pancreatic signals controlling food intake; insulin, glucagon and amylin
  49. Amylin deposition in the kidney of patients with diabetic nephropathy
  50. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell …
  51. Copper (II) inhibits the formation of amylin amyloid in vitro
  52. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR
  53. Tissue expression and secretion of amylin
  54. Induction of insulin resistance in vivo by amylin and calcitonin gene–related peptide
  55. Inhibition of central amylin signaling increases food intake and body adiposity in rats
  56. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro
  57. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes
  58. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product
  59. The aggregation potential of human amylin determines its cytotoxicity towards islet β‐cells
  60. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process
  61. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies
  62. Insights into amylin–leptin synergy
  63. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma
  64. Central amylin acts as an adiposity signal to control body weight and energy expenditure
  65. Brainstem mechanisms of amylin-induced anorexia
  66. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms
  67. Comparison of the effects of calcitonin gene‐related peptide and amylin on osteoblasts
  68. Amylin and bone metabolism in streptozotocin‐induced diabetic rats
  69. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or-3
  70. Synergy between amylin and cholecystokinin for inhibition of food intake in mice
  71. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus
  72. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT)
  73. Aβ and human amylin share a common toxicity pathway via mitochondrial dysfunction
  74. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats
  75. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
  76. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
  77. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1
  78. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis
  79. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle.
  80. Amylin receptor blockade stimulates food intake in rats
  81. Amylin
  82. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily
  83. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro.
  84. A” is for amylin and amyloid in type 2 diabetes mellitus
  85. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
  86. Protection by amylin of gastric erosions induced by indomethacin or ethanol in rats
  87. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic …
  88. S20G mutation of the amylin gene is associated with Type II diabetes in Japanese
  89. Modulation of food intake by peripherally administered amylin
  90. Role of aromatic interactions in amyloid formation by peptides derived from human amylin
  91. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid-and human amylin-induced toxicity
  92. Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state
  93. Evidence for a partially structured state of the amylin monomer
  94. Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin
  95. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats
  96. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors
  97. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
  98. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide
  99. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition
  100. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year …
  101. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin)
  102. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight
  103. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation
  104. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose …
  105. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat
  106. Control of food intake and energy expenditure by amylin—therapeutic implications
  107. Cosecretion of amylin and insulin from isolated rat pancreas
  108. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice
  109. Islet amyloid polypeptide (amylin) is expressed in sensory neurons
  110. Molecular basis for the recognition and cleavages of IGF-II, TGF-α, and amylin by human insulin-degrading enzyme
  111. Interaction of leptin and amylin in the long‐term maintenance of weight loss in diet‐induced obese rats
  112. Solution structures of rat amylin peptide: simulation, theory, and experiment
  113. Antiobesity effects of the β-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression
  114. In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit
  115. Solution state structures of human pancreatic amylin and pramlintide
  116. Amylin regulation of carbohydrate metabolism.
  117. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors
  118. Rat amylin: cloning and tissue-specific expression in pancreatic islets.
  119. Fatty acids induce amylin expression and secretion by pancreatic β-cells
  120. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes
  121. Human but not rat amylin shares neurotoxic properties with Aβ42 in long-term hippocampal and cortical cultures
  122. Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus
  123. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients
  124. In vivo central actions of rat amylin
  125. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP
  126. Actions of amylin on subfornical organ neurons and on drinking behavior in rats
  127. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats
  128. Pharmacology of receptors for calcitonin gene-related peptide and amylin
  129. Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid
  130. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans.
  131. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
  132. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity
  133. Human aging is associated with parallel reductions in insulin and amylin release
  134. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 …
  135. Amyloid β and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP‐1 cells and murine microglia
  136. Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1
  137. Amylin in the periphery II: an updated mini-review
  138. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
  139. Co-secretion of amylin and insulin from cultured islet β-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents
  140. Amylin and its relation to insulin and lipids in obese children before and after weight loss
  141. Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK
  142. Stimulation of both aerobic glycolysis and Na+-K+-ATPase activity in skeletal muscle by epinephrine or amylin
  143. In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain
  144. Syntheses, structures and anorectic effects of human and rat amylin
  145. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy
  146. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues
  147. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes
  148. Amylin: physiology and pharmacology
  149. Antiulcer effects of amylin: a review
  150. Neurotoxicity of Human Amylin in Rat Primary Hippocampal Cultures: Similarity to Alzheimer’s Disease Amyloid‐β Neurotoxicity
  151. Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin
  152. Heparin-binding properties of the amyloidogenic peptides Aβ and amylin: dependence on aggregation state and inhibition by Congo red
  153. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypeptide (amylin) fibril formation.
  154. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas
  155. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
  156. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas
  157. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats
  158. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology.
  159. Does neuropeptide Y contribute to the anorectic action of amylin?
  160. The role of neuropeptide Y, orexins, cocaine and amphetamine-related transcript, cholecystokinin, amylin and leptin in the regulation of feeding in fish
  161. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice
  162. The acute effect of amylin and salmon calcitonin on energy expenditure
  163. Thiol reducing compounds prevent human amylin‐evoked cytotoxicity
  164. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host …
  165. Identification of central projections from amylin-activated neurons to the lateral hypothalamus
  166. Amylin and the gastrointestinal tract
  167. Role of amylin in nutrient intake–animal studies
  168. Amylin stimulates plasma renin concentration in humans
  169. Alzheimer’s β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic …
  170. Area postrema and the anorectic actions of dexfenfluramine and amylin
  171. Pancreatic cancer cells selectively stimulate islet β cells to secrete amylin
  172. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications
  173. Amylin and glucose co-activate area postrema neurons of the rat
  174. Amylin fasting plasma levels are decreased in patients with osteoporosis
  175. The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit.
  176. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
  177. Copper-mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus?
  178. Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior
  179. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin
  180. Amylin–its physiological role in humans
  181. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats
  182. Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions
  183. Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice
  184. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts
  185. Anorexia following the systemic injection of amylin
  186. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1
  187. Human amylin induces “apoptotic” pattern of gene expression concomitant with cortical neuronal apoptosis
  188. Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation
  189. Effects of calcitonin gene-related peptide and amylin on human osteoblast-like cells proliferation
  190. Effects of amylin on feeding of goldfish: interactions with CCK
  191. Amylin and food intake in mice: effects on motivation to eat and mechanism of action
  192. Distribution and kinetics of amylin in humans
  193. Amylin and insulin interact to reduce food intake in rats
  194. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption
  195. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas
  196. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes
  197. Nano‐Scale Imaging and Dynamics of Amylin‐Membrane Interactions and Its Implication in Type II Diabetes Mellitus
  198. Amylin is associated with delayed gastric emptying in critically ill children
  199. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle
  200. Mechanism of action of amylin in bone
  201. Behavioral effects of amylin injected intracerebroventricularly in the rat
  202. Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β‐cells
  203. Effects of amylin and the amylin agonist pramlintide on glucose metabolism
  204. Vaspin and amylin are expressed in human and rat placenta and regulated by nutritional status
  205. Amylin and adrenomedullin: novel regulators of bone growth
  206. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes
  207. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats
  208. Effects of amylin on appetite regulation and memory
  209. Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat
  210. Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences
  211. Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats
  212. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin
  213. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
  214. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa
  215. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity
  216. Immunohistochemical localization of amylin in rat brainstem☆,☆☆
  217. Amylin and the integrated control of nutrient influx
  218. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue
  219. The role of amylin and related peptides in osteoporosis
  220. Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet β-cells
  221. Design and study of peptide-based inhibitors of amylin cytotoxicity
  222. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats
  223. Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia
  224. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial
  225. Combination therapy with amylin and peptide YY [3–36] in obese rodents: anorexigenic synergy and weight loss additivity
  226. Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat
  227. Amylin-based pharmacotherapy-past, present & future
  228. Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice
  229. Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in the rat: evidence for a metabolic role of endogenous amylin
  230. Effect of the disulfide bond on the monomeric structure of human amylin studied by combined Hamiltonian and temperature replica exchange molecular dynamics …
  231. Amylin injection causes elevated plasma lactate and glucose in the rat
  232. Central amylin signaling and the regulation of energy homeostasis
  233. Serum levels of proamylin and amylin in normal subjects and patients with impaired glucose regulation and type 2 diabetes mellitus
  234. Processing of synthetic pro‐islet amyloid polypeptide (proIAPP) ‘amylin’ by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro
  235. Effects of amylin and adrenomedullin on the skeleton
  236. Amylin‐amide: a new bone‐conserving peptide from the pancreas
  237. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets
  238. Systemic administration of a novel octapeptide, amylin-(1—8), increases bone volume in male mice
  239. Inhibition of Amyloid Fibril Formation of Human Amylin by N‐Alkylated Amino Acid and α‐Hydroxy Acid Residue Containing Peptides
  240. Effects of adrenomedullin, calcitonin gene-related peptide, and amylin on cerebral circulation in dogs
  241. Autoradiographic distribution and receptor binding profile of [125I] Bolton Hunter-rat amylin binding sites in the rat brain.
  242. Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin
  243. Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells
  244. Conformational preferences of the amylin nucleation site in SDS micelles: an NMR study
  245. Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers
  246. Amylin and amylin-amide lack an acute effect on blood glucose and insulin
  247. Antagonist of the amylin receptor blocks β-amyloid toxicity in rat cholinergic basal forebrain neurons
  248. Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat
  249. Effects of amylin on human osteoblast-like cells
  250. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function
  251. Roles of amylin in satiation, adiposity and brain development
  252. Pharmacological characterisation of amylin-related peptides activating subfornical organ neurones
  253. Amylin in bone conservation current evidence and hypothetical considerations
  254. Hypertrophic effects of calcitonin gene-related peptide (CGRP) and amylin on adult mammalian ventricular cardiomyocytes
  255. Sedimentation studies on human amylin fail to detect low-molecular-weight oligomers
  256. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney
  257. Changes in Amylin and Amylin-Like Peptide Concentrations ana (β-Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM
  258. In vitro effects of amylin on carbohydrate metabolism in liver cells
  259. Age-related changes in amylin secretion
  260. Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21WAF1/CIP1
  261. Amylin release during oral glucose tolerance test
  262. Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation
  263. Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance
  264. The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels
  265. Structural diversity of the soluble trimers of the human amylin (20–29) peptide revealed by molecular dynamics simulations
  266. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin
  267. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice
  268. Fas-associated death receptor signaling evoked by human amylin in islet β-cells
  269. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes
  270. Amylin given by central and peripheral routes inhibits acid gastric secretion
  271. Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling.
  272. Amylin reduces food intake more potently than calcitonin gene-related peptide (CGRP) when injected into the lateral brain ventricle in rats
  273. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product
  274. Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats
  275. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development
  276. Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet β-cells
  277. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked …
  278. Anti-insulin effects of amylin and calcitonin-gene-related peptide on hepatic glycogen metabolism
  279. Extra-pancreatic expression of the rat islet amyloid polypeptide (amylin) gene
  280. Amylin-induced cytotoxicity is associated with activation of caspase-3 and MAP kinases
  281. Deletions of genes encoding calcitonin/a-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors …
  282. Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms
  283. Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting
  284. Anorectic effects of amylin in rats over the life span
  285. Amylin and gastrointestinal activity
  286. Amylin tonally regulates arginine-stimulated insulin secretion in rats
  287. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk
  288. Islet amyloid polypeptide (IAPP; amylin) influences the endocrine but not the exocrine rat pancreas
  289. Amylin in the periphery
  290. Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes
  291. Effect of race and hypertension on plasma amylin concentrations
  292. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo
  293. Postprandial response of plasma insulin, amylin and acylated ghrelin to various test meals in lean and obese cats
  294. Amylin regulation of fuel metabolism
  295. Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin
  296. High-frequency oscillations in circulating amylin concentrations in healthy humans
  297. Promotion of β-structure by interaction of diabetes associated polypeptide (amylin) with phosphatidylcholine
  298. Exenatide. Amylin/Eli Lilly.
  299. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism
  300. Glucoregulatory endocrine responses to intermittent exercise of different intensities: Plasma changes in a pancreatic [beta]-cell peptide, amylin
  301. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans
  302. Effects of centrally injected amylin on sexual behavior of male rats
  303. The regulation of amylin and insulin gene expression and secretion
  304. The specificity of amylin for the diagnosis of pancreatic adenocarcinoma
  305. Spontaneous diabetes in hemizygous human amylin transgenic mice that developed neither islet amyloid nor peripheral insulin resistance
  306. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C‐peptide concentrations in patients with type 2 diabetes
  307. Solution structures of calcitonin-gene-related-peptide analogues of calcitonin-gene-related peptide and amylin
  308. Amylin causes anorexigenic effects via the hypothalamus and brain stem in chicks
  309. In-vitro and in-vivo antagonistic action of an anti-amylin Spiegelmer
  310. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment
  311. Optimizing diabetes treatment using an amylin analogue
  312. Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats
  313. Activation of amylin gene transcription by LIM domain homeobox gene isl-1.
  314. Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists
  315. Synthesis and structural investigations of N-alkylated β-peptidosulfonamide–peptide hybrids of the amyloidogenic amylin (20–29) sequence: implications of …
  316. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin
  317. Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects
  318. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man
  319. Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
  320. Amylin as a growth factor during fetal and postnatal development of the rat kidney
  321. Amylin inhibits ovariectomy-induced bone loss in rats
  322. Amylin and severe acute pancreatitis
  323. Effects of rat amylin on renal function in the rat
  324. Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus
  325. Differential effects of amylin on memory processing using peripheral and central routes of administration
  326. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal anti-inflammatory drugs
  327. Prevention and promotion effects of apolipoprotein E4 on amylin aggregation
  328. Increased levels of plasma amylin in advanced renal failure.
  329. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity
  330. Effects of amylin deficiency on trabecular bone in young mice are sex-dependent
  331. Transformation of the amyloidogenic peptide amylin (20–29) into its corresponding peptoid and retropeptoid: Access to both an amyloid inhibitor and template for self …
  332. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRPα) …
  333. The threshold of amylin-induced anorexia is lower in chicks selected for low compared to high juvenile body weight
  334. Amylin and diabetes.
  335. Amylin peptide is increased in preterm neonates with feed intolerance
  336. Amylin suppresses acetic acid-induced visceral pain and spinal c-fos expression in the mouse
  337. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent …
  338. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus
  339. Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor
  340. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus
  341. Vasodilator responses to calcitonin gene-related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP1 receptors.
  342. Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation
  343. Amylin increases bone volume but cannot ameliorate diabetic osteopenia
  344. Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension
  345. Involvement of multiple receptors in the biological effects of calcitonin gene‐related peptide and amylin in rat and guinea‐pig preparations
  346. Nephrectomy decreases amylin and pramlintide clearance in rats
  347. Skeletal effects of amylin and related peptides
  348. Investigation on the mechanisms involved in the central protective effect of amylin on gastric ulcers in rats
  349. Amylin and Hypertension: Association of an Amylin− G132A Gene Mutation and Hypertension in Humans and Amylin-Induced Endothelium Dysfunction in Rats
  350. Special report regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved
  351. Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori
  352. Human amylin stimulates inflammatory cytokine secretion from human glioma cells
  353. Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.
  354. Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension
  355. Amylin (1–8) is devoid of anabolic activity in bone
  356. Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats
  357. β-Structure in human amylin and 2 designer β-peptides: CD and NMR spectroscopic comparisons suggest soluble β-oligomers and the absence of significant …
  358. Rapid publication: Hypocalcemic actions of amylin amide in humans
  359. Self‐Assembly of Amylin (20–29) Amide‐Bond Derivatives into Helical Ribbons and Peptide Nanotubes rather than Fibrils
  360. Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents
  361. Histamine H1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin
  362. Amylin/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate
  363. Protective effects of amylin on reserpine-induced gastric damage in the rat
  364. Aspects of secretion and actions of amylin: interplay between amylin and other hormones.
  365. Characterization of amylin and calcitonin receptor binding in the mouse α-thyroid-stimulating hormone thyrotroph cell line
  366. Adrenomedullin, amylin, calcitonin gene-related peptide and their fragments are potent inhibitors of gastric acid secretion in rats
  367. Amylin-mediated inhibition of insulin-stimulated glucose transport in skeletal muscle
  368. Amylin increases transport of tyrosine and tryptophan into the brain
  369. Effects of glucagon, insulin, amylin and CGRP on feeding
  370. Neuroendocrine actions of amylin
  371. Receptors for calcitonin gene-related peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity-modifying proteins
  372. Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide: interventional studies in humans
  373. Presence of liver CGRP/amylin receptors in only nonparenchymal cells and absence of direct regulation of rat liver glucose metabolism by CGRP/amylin
  374. Amylin and syndrome‐X
  375. Production of cAMP by adrenomedullin in human oligodendroglial cell line KG1C: comparison with calcitonin gene-related peptide and amylin
  376. Diet-derived nutrients modulate the effects of amylin on c-Fos expression in the area postrema and on food intake
  377. Effect of amylin in various experimental models of gastric ulcer
  378. Daily amylin replacement reverses hepatic glycogen depletion in insulin‐treated streptozotocin diabetic rats
  379. Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients
  380. The chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and formation of β-sheet-containing aggregates by human amylin: a potential role …
  381. Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors
  382. Distribution of amylin-immunoreactive neurons in the monkey hypothalamus and their relationships with the histaminergic system
  383. Differential responses of circulating amylin to high‐fat vs. high‐carbohydrate meal in healthy men
  384. Basal plasma levels of insulin, leptin, ghrelin, and amylin do not signal adiposity in rats recovering from forced overweight
  385. Differential effects of amylin and salmon calcitonin on neuropeptide gene expression in the lateral hypothalamic area and the arcuate nucleus of the rat
  386. Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes
  387. Differential calcitonin gene‐related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP/amylin receptor …
  388. Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum
  389. Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats
  390. Microwave assisted SPPS of amylin and its toxicity of the pure product to RIN‐5F cells
  391. Expression of human islet amyloid polypeptide/amylin impairs insulin secretion in mouse pancreatic β cells
  392. Understanding Amylin Receptors
  393. Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas
  394. IAPP/amylin gene transcriptional control region: evidence for negative regulation
  395. Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: a sign of impaired β-cell function?
  396. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide
  397. Atomic force microscopy study of human amylin (20-29) fibrils
  398. Positive inotropic, positive chronotropic and coronary vasodilatory effects of rat amylin: mechanisms of amylin-induced positive inotropy
  399. Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat
  400. Amylin replacement therapy in patients with type 1 diabetes
  401. Effects of amylin on the release of insulin and glucagon from the perfused rat pancreas
  402. Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity
  403. Arcuate neurons of overweight rats differ in their responses to amylin from controls
  404. Release of amylin from perfused rat pancreas in response to glucose, arginine, β-hydroxybutyrate, and gliclazide
  405. Amylin, released from the gastric fundus, stimulates somatostatin and thus inhibits histamine and acid secretion in mice
  406. Amylin increases cyclic AMP formation in L6 myocytes through calcitonin gene-related peptide receptors
  407. Immunoreactivity and expression of amylin in gastroenteropancreatic endocrine tumors.
  408. Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus
  409. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output
  410. Relative hypersecretion of amylin to insulin from rat pancreas after neonatal STZ treatment
  411. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus
  412. Effect of insulin, proinsulin, and amylin on renin release from perfused rat kidney
  413. Molecular forms of islet amyloid polypeptide (IAPP/amylin) in four mammals
  414. Amylin analogue as an antidiabetic agent
  415. Rat amylin-(8—37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats
  416. Amylin or CGRP (8–37) fragments reverse amylin-induced inhibition of 14C-glycogen accumulation
  417. Amylin, amyloid and age-related disease
  418. Increased density of renal amylin binding sites in experimental hypertension
  419. Amylin mobilizes [Ca2+] i and stimulates the release of pancreatic digestive enzymes from rat acinar AR42J cells: evidence for an exclusive receptor system of amylin
  420. Attenuation of the anorectic effects of cholecystokinin and bombesin by the specific amylin antagonist AC 253
  421. The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors
  422. CGRP receptors mediating CGRP‐, adrenomedullin‐and amylin‐induced relaxation in porcine coronary arteries. Characterization with ‘Compound 1′(WO98/11128), a …
  423. Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney
  424. Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP (8–37)
  425. Behaviorally specific inhibition of sham feeding by amylin
  426. Chronic infusion of the amylin antagonist AC 187 increases feeding in Zucker fa/fa rats but not in lean controls
  427. Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard …
  428. Interaction of amylin with calcitonin gene‐related peptide receptors in the microvasculature of the hamster cheek pouch in vivo
  429. Pharmacokinetics and pharmacodynamics of AC137 (25, 28, 29 tripro‐amylin, human) after intravenous bolus and infusion doses in patients with insulin‐dependent …
  430. Gastric amylin expression: cellular identity and lack of requirement for the homeobox protein PDX-1. A study in normal and PDX-1-deficient animals with a cautionary …
  431. Biotinyl analogues of amylin as biologically active probes for amylin/CGRP receptor recognition
  432. Preliminary report Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other …
  433. Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of beta-amyloid effects
  434. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20− 29 of amylin revealed by solid-state NMR and X-ray fiber diffraction
  435. Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors
  436. Molecular model-building of amylin and α-calcitonin gene-related polypeptide hormones using a combination of knowledge sources
  437. Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin
  438. Increased secretion of amylin in women with polycystic ovary syndrome
  439. Amylin in pancreatic islets and pancreatic endocrine neoplasms
  440. Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria
  441. Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus
  442. Islet amyloid polypeptide (amylin) modulates chylomicron metabolism in rats
  443. Stimulation of adenylate cyclase by amylin in CHO-K1 cells.
  444. Amylin immunoreactivity in the rat trachea and characterization of the interaction of amylin and somatostatin on airway mucus secretion
  445. In vivo glucose-stimulated amylin secretion is increased in nondiabetic patients with pancreatic cancer
  446. The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm
  447. Molecular characterization of calcitonin gene-related peptide (CGRP) related peptides (CGRP, amylin, adrenomedullin and adrenomedullin-2/intermedin) in goldfish …
  448. S20G mutation of the amylin gene is associated with a lower body mass index in Korean type 2 diabetic patients
  449. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial …
  450. Amylin is an agonist of the renal porcine calcitonin receptor
  451. The amylin superfamily: A novel grouping of biologically active polypeptides related to the insulin A-chain
  452. Immunohistochemical localization of amylin in human pancreas, thyroid, pituitary and their tumors
  453. Activity of amylin at CGRP1-preferring receptors coupled to positive contractile response in rat ventricular cardiomyocytes
  454. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin
  455. Multiple receptors for calcitonin gene-related peptide and amylin on guinea-pig ileum and vas deferens.
  456. Comparison of Fos induced in rat brain by GLP-1 and amylin
  457. Amylin release from perfused rat pancreas in response to glucose and arginine
  458. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene.
  459. Islet amyloid polypeptide (IAPP/amylin) causes insulin resistance in perfused rat hindlimb muscle
  460. S20G mutation of the amylin gene in Japanese patients with type 2 diabetes
  461. Control of glycogen synthase and phosphorylase by amylin in rat skeletal muscle. Hormonal effects on the phosphorylation of phosphorylase and on the …
  462. Unresolved Challenges with Insulin Therapy in Type 1 and Type 2 Diabetes: Potential Benefit of Replacing Amylin, a Second β-Cell Hormone
  463. Positive inotropy of calcitonin gene-related peptide and amylin on porcine isolated myocardium
  464. Pramlintide (Amylin).
  465. … rat hindlimb is increased after glucose-administration and is suppressed by a selective amylin antagonist: evidence for action of endogenous amylin in skeletal muscle
  466. Delayed fibril formation of amylin (20–29) by incorporation of alkene dipeptidosulfonamide isosteres obtained by solid phase olefin cross metathesis
  467. Circadian anorectic effects of peripherally administered amylin in rats.
  468. Effects of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide (CGRP) on glucose metabolism in the rat
  469. Pancreatic amylin content in human diabetic subjects and its relation to diabetes
  470. Stimulatory effects of islet amyloid polypeptide (amylin) on exocrine pancreas and gastrin release in conscious rats
  471. Effects of amylin and other peptide hormones on Na+–K+ transport and contractility in rat skeletal muscle
  472. Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice
  473. Plasma amylin concentration is related to the severity of intestinal ischemic injury in rats
  474. Reduction of islet amylin expression and basal secretion by adenovirus-mediated delivery of amylin antisense cDNA
  475. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure
  476. Evidence for release of free glucose from muscle during amylin-induced glycogenolysis in rats
  477. Influence of glucose concentration on the inhibitory effect of amylin on insulin secretion. Study in the perfused rat pancreas
  478. Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation
  479. The physiology of calcitonin gene-related peptide in the islet compared with that of islet amyloid polypeptide (amylin).
  480. Amylin evokes phosphorylation of P20 in rat skeletal muscle
  481. Amylin (islet amyloid polypeptide) inhibition of insulin release in the perfused rat pancreas: implication of the adenylate cyclase/cAMP system
  482. Acute application of human amylin, unlike β-amyloid peptides, kills undifferentiated PC12 cells by apoptosis
  483. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in type 1 diabetic subjects
  484. Adrenomedullin increases cyclic AMP more potently than CGRP and amylin in rat renal tubular basolateral membranes
  485. The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat …
  486. Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum …
  487. Characterization of amylin binding sites in a human hepatoblastoma cell line
  488. Amylin S20G mutation in Mexican population
  489. Amylin-induced suppression of ANP secretion through receptors for CGRP1 and salmon calcitonin
  490. Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli. Study in perfused rat pancreas.
  491. … hydroxyphenyl) methyl]-2-oxoethyl]-4-(1, 4-dihydro-2-oxo-3 (2H)-quinazolinyl)(BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors—the role …
  492. Effect of amylin on the tone of rat aorta ring preparation
  493. Developmental Regulation of Amylin and Insulin-Gene Expression in Lean (Fa/Fa) and obese (fa/fa) Zucker rats
  494. Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice
  495. Metabolic effects of amylin in lactating goats
  496. Effects of amylin on bone development and egg production in hens
  497. The effects of amylin on motivated behavior in rats
  498. Effects of amylin and salmon calcitonin on feeding and drinking behavior in pygmy goats
  499. Different influence of CGRP (8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats
  500. Insulin upstream factor 1 and a novel ubiquitous factor bind to the human islet amyloid polypeptide/amylin gene promoter
  501. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
  502. Aggregation of liposomes induced by the toxic peptides Alzheimer’s Aβs, human amylin and prion (106–126): facilitation by membrane-bound GM1 ganglioside
  503. Dose-dependent elevation of cyclic AMP, activation of glycogen phosphorylase, and release of lactate by amylin in rat skeletal muscle
  504. The effect of adrenomedullin, amylin fragment 8-37 and calcitonin gene-related peptide on contractile force, heart rate and coronary perfusion pressure in isolated rat …
  505. Amylin in human pancreatic islets
  506. Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats
  507. Amylin is more potent and more effective than glucagon in raising plasma glucose concentration in fasted, anesthetized rats
  508. Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin
  509. The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils
  510. Hypersecretion of amylin from the perfused pancreas of genetically obese (fafa) rats and its alteration with aging
  511. Biological action of pancreatic amylin: relationship with glucose metabolism, diabetes, obesity and calcium metabolism.
  512. Amylin and epinephrine have no direct effect on glucose transport in isolated rat soleus muscle
  513. The role of sensory neurons in the antiulcer effect of centrally injected amylin in rat
  514. Amylin inhibits insulin-stimulated glucose uptake in C2C12 muscle cell line through a cholera-toxin-sensitive mechanism
  515. Amylin, calcitonin gene-related peptide, and adrenomedullin: effects on thiazide receptor and calcium
  516. GABAA receptor antagonists prevent abnormalities in leptin, insulin and amylin actions on paraventricular hypothalamic neurons of overweight rats
  517. Amylin reduces plasma glucagon concentration in cats
  518. Lack of effect of calcitonin gene-related peptide and amylin on major markers of glucose metabolism in hepatocytes
  519. The effects of amylin on insulin secretion from Rin m5F cells and glycogen synthesis and lipogenesis in rat primary cultured hepatocytes
  520. Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats
  521. Impaired phasic insulin and amylin secretion in diabetic rats
  522. Optimizing treatment success with an amylin analogue
  523. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo …
  524. Islet amyloid polypeptide/amylin in pancreatic β-cell line derived from transgenic mouse insulinoma
  525. Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8–37 fragment of human CGRP
  526. Islet amyloid polypeptide/amylin messenger RNA and protein expression in human insulinomas in relation to amyloid formation
  527. Amylin analogue in the treatment of obesity
  528. Amylin replacement therapy in patients with insulin-requiring type 2 diabetes
  529. Post-partum evaluation of amylin in lean patients with gestational diabetes mellitus
  530. Characterization of the human islet amyloid polypeptide/amylin gene transcripts: identification of a new polyadenylation site
  531. Biologically active human islet amyloid polypeptide/amylin in transgenic mice
  532. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas
  533. S15261 antagonises amylin-induced impaired glucose tolerance
  534. Plasma amylin concentrations in fasted and fed rats quantified by a monoclonal immunoenzymometric assay
  535. Responsiveness to Leptin Restored by Amylin in Diet Induced Obese (DIO) Rats: Magnitude and Mechanisms of Synergy.
  536. Sex steroids do not prevent amylin-induced apoptosis in human cells
  537. Amylin induces natriuresis by a central angiotensin-dependent mechanism
  538. Role of amylin in glucose homeostasis and its perspective use in diabetes management
  539. Islet amyloid polypeptide (amylin) increases the renal excretion of calcium in the conscious dog
  540. A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor
  541. Amylin and hypertension: the status of the current debate
  542. 8–37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats
  543. Insulin treatment improves relative hypersecretion of amylin to insulin in rats with non-insulin-dependent diabetes mellitus induced by neonatal streptozocin injection
  544. Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat in vivo
  545. Regulation of amylin release from cultured rabbit gastric fundic mucosal cells
  546. Islet amyloid polypeptide/amylin contents in pancreata increase in genetically obese and diabetic mice
  547. Non-competitive antagonism of amylin on CGRP1-receptors in rat coronary small arteries
  548. Analysis of rat amylin amide from commercial sources: Identification of a mercury complex.
  549. Amylin gene expression mediated by cAMP/PKA and transcription factors HNF-1 and NFY
  550. AMYLIN-CONTAINING CELLS IN THE GASTRO-ENTERO-PANCREATIC (GEP) ENDOCRINE SYSTEM OF THE RAT AND HUMANS AN IMMUNOHISTOCHEMICAL …
  551. Effects of exogenous somatostatin and insulin on islet amyloid polypeptide (amylin) release from perfused rat pancreas
  552. … adenylate cyclase by amylin and CGRP: A single receptor displaying apparent negative cooperativity towards CGRP and simple saturation kinetics for amylin, a …
  553. Insulin-like growth factor-I inhibits insulin and amylin secretion in conscious rats
  554. Amylin as a neuroendocrine hormone
  555. … for 125I-labelled human alpha calcitonin gene related peptide ([125I] hCGRP alpha) and 125I-labelled Bolton-Hunter rat amylin ([125I] BHrAMY) specific binding sites …
  556. … or negative-co-operativity model for the activation of adenylate cyclase by a common G-protein-coupled calcitonin-gene-related neuropeptide (CGRP)/amylin receptor
  557. The stimulatory effect of amylin on mucus secretion in isolated rat trachea
  558. Unimpaired effect of insulin on glucokinase gene expression in hepatocytes challenged with amylin
  559. Section Review Oncologic, Endocrine & Metabolic: The amylin, CGRP and calcitonin family of peptides
  560. Gestational diabetes mellitus is associated with an increase in the total concentration of amylin molecules
  561. GSK3 involvement in amylin signaling in isolated rat soleus muscle
  562. Increased secretion and expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 (7–36)
  563. Pancreatic hormone amylin and integrity of the gastric mucosa
  564. Induction of acute hyperglycemia, hyperlactemia and hypocalcemia in fed and fasted BALB/c mice by intravenous amylin injection
  565. Mercury in a commercial preparation of rat amylin.
  566. Amylin alters the biological action of the incretin hormone GLP-1 (7-36) amide
  567. Leapin’lizards: Amylin targets diabetes and obesity via incretins
  568. 8–37h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo
  569. Activation of activating transcription factor 2 by p38 MAP kinase during apoptosis induced by human amylin in cultured pancreatic β‐cells
  570. Chapter viii calcitonin gene-related peptide (cgrp), amylin and adrenomedullin: anatomical localization and biological functions in the mammalian and human brains
  571. Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa
  572. Development and characterization of monoclonal antibodies specific for amylin
  573. Enterostatin decreases postprandial pancreatic UCP2 mRNA levels and increases plasma insulin and amylin
  574. Intestinal ischaemia-reperfusion increases plasma amylin concentration in rats
  575. Effects of amylin and salmon calcitonin on β-endorphin-induced growth hormone and prolactin secretion in the rat
  576. Human amylin mimicks amyloid β protein-induced reactive gliosis and inhibition of cellular redox activity in cultured astrocytes
  577. Nucleotide sequence of a cDNA for canine amylin
  578. Amylin peptide levels are raised in infants of diabetic mothers
  579. INVOLVEMENT OF DA1AND DA2RECEPTORS IN THE GASTROPROTECTIVE ACTIVITY OF AMYLIN IN THE RAT
  580. Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal
  581. Cardiac consequences of increased amylin secretion in diabetics
  582. Synthesis of biologically active tritiated amylin and salmon calcitonin analogues
  583. Histamine H1-receptors differentially mediate the action of amylin on hypothalamic neurons in control and in overweight rats
  584. Fibrillogenic amylin evokes the apoptosis of human mesangial cells
  585. What makes an amylin receptor?
  586. Strong Promoter Activity of Human and Rat Islet Amyloid Polypeptide/Amylin Gene Constructs in Mouse Beta Cells (βTC 3)
  587. Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome
  588. The CGRP family: calcitonin gene-related peptide (CGRP), amylin and adrenomedullin
  589. Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist …
  590. Effect of amylin on prolactin release
  591. Alpha2-adrenoceptors and the regulation of glucose, insulin and amylin levels in diabetic rats
  592. The ability of amylin to reduce eating depends on the protein content of the diet
  593. … for identifying simple sequence repeat DNA polymorphisms near cloned cDNAs and genes: linkage studies of the islet amyloid polypeptide/amylin and liver glycogen …
  594. Islet amyloid polypeptide (amylin) does not seem to be directly involved in the development of gestational diabetes mellitus
  595. Integrated neurohormonal approach to the treatment of obesity: the amylin agonist pramlintide and its interactions with leptin and PYY signaling pathways
  596. Transient increase of rat gastric amylin in the neonatal period and in experimental ulcers
  597. Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats
  598. Renal amylin binding in normotensive and hypertensive rats: effects of angiotensin converting enzyme inhibition with perindopril
  599. Amylin/IAPP (islet amyloid polypeptide)–physiology and clinical significance
  600. Amylin, the kidney and hypertension
  601. Backbone‐modified amylin derivatives: implications for amyloid inhibitor design and as template for self‐assembling bionanomaterials
  602. Mirror image supramolecular helical tapes formed by the enantiomeric-depsipeptide derivatives of the amyloidogenic peptide amylin (20–29)
  603. Effect of (8–32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat
  604. High plasma amylin/islet amyloid polypeptide levels in patients with residual medullary thyroid carcinoma after total thyroidectomy
  605. β-cell tropin-and glucose-induced hypersecretion of insulin and amylin from perfused fatty rat pancreas
  606. Calcitonin gene-related peptide-induced suppression of atrial natriuretic peptide release through receptors for CGRP1 but not for calcitonin and amylin
  607. Amylin/islet amyloid polypeptide expression in medullary carcinoma of the thyroid: correlation with the expression of the related calcitonin/CGRP genes
  608. Administration of human amylin increases plasma renin activity and plasma aldosterone in man.
  609. Direct inhibitory effect of adrenomedullin, calcitonin gene-related peptide, calcitonin, and amylin on cholecystokinin-induced contraction of guinea-pig isolated caecal …
  610. Interaction of Human Amylin with Phosphatidylcholine and Phosphatidylserine Membranes
  611. The vasorelaxant effect of adrenomedullin, proadrenomedullin N‐terminal 20 peptide and amylin in human skin
  612. Amylin Expression in the Pancreatic β-Cell
  613. Inhibitory effect of amylin on growth hormone responsiveness to growth-hormone-releasing hormone in the rat
  614. Amylin impairment of insulin effects on glycogen synthesis and phosphoenolpyruvate carboxykinase gene expression in rat primary cultured hepatocytes
  615. Agouti Signaling Protein Stimulates Islet Amyloid Polypeptide (Amylin) Secretion in Pancreatic β-Cells
  616. Effect of synthetic human amylin on glycogen synthesis in skeletal muscle in vivo
  617. Release of amylin from perfused rat pancreas in response to glucose and glucagon
  618. Molecular form of islet amyloid polypeptide (amylin) released from isolated rat islets of Langerhans
  619. Determinants of BIBN4096BS affinity for CGRP and amylin receptors; the role of RAMP1
  620. Effect of amylin on islet cell secretion
  621. Mercury contamination of rat amylin mimics vasoactivity and cytotoxic effects
  622. Pramlintide (human amylin analogue) as an adjunct to insulin therapy in patients with type 1 diabetes improved glycemic control over 2 years
  623. Effect of amylin on mast cell secretion as a possible mechanism increasing gastric mucosa resistance
  624. Amylin does not suppress hypoglycemia-induced secretion of glucagon in rats
  625. Amylin-immunoreactivity in monkey hypothalamus
  626. Effects of pancreatic polypeptide amylin on ulceration and acid gastric Secretion
  627. Calcitonin gene-related peptide (CGRP), adrenomedullin (AM), amylin, and calcitonin (CT) receptors and overlapping biological actions
  628. The selective amylin antagonist, AC413, prevents sucrose-induced increases in mean arterial pressure in rats.
  629. Compared to wild-type human amylin, S20G mutant amylin exhibits increased cytotoxicity in transfected COS-1 cells and increased amyloidogenicity in vitro
  630. An amylin antagonist has opposite effects to amylin on basal lipids and counteracts insulin resistance in high fat fed rats
  631. Therapeutic potential of human amylin analogues in diabetes mellitus
  632. Amylin evokes protein p20 phosphorylation and insulin resistance in rat skeletal muscle extensor digitorum longus
  633. Diabetes II and amylin: a modern perspective
  634. Amylin and calcitonin gene-related peptide
  635. The effects of systemic administration of amylin on the tibia of laying hens
  636. Hepatocyte nuclear factor 1 negatively regulates amylin gene expression
  637. 5. New Type of Amyloidosis b) Islet Amyloid Polypeptide (IAPP/Amylin) in Non-Insulin-Dependent Diabetes Mellitus
  638. Role of amylin in the pathogenesis of type II diabetes mellitus
  639. Effect of islet amyloid polypeptide (IAPP/amylin) on 2-deoxyglucose uptake in mouse pancreatic acini
  640. –To: Poa NR, Cooper GJS, Edgar PF: Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46: 574–578
  641. Additive effect of islet amyloid polypeptide (IAPP/amylin) and insulin on 2-deoxyglucose uptake in mouse pancreatic acini
  642. Amylin and Incretin Enhancers for Diabetes Type 2
  643. Amylin: its potential role in the etiopathogenicity of diabetes mellitus
  644. Amylin hormone, leptin and other metabolic hormones in preterm babies
  645. Advance of the relation in amylin and insulin resistance
  646. Construction of transgenic mouse system expressing human islet amyloid polypeptide (IAPP)/amylin
  647. Amylin competes for binding sites of CGRP in the chamber angle and uvea of monkey, cat, and pig eye
  648. Amylin and Calcitonin Gene-Related Peptide
  649. β‐Amyloid peptides 1–40βA and 25–35βA suppress human amylin‐mediated death of RINm5F islet β‐cells with distinct actions on fibril formation
  650. Amyloidogenic peptides such as beta-amyloid, amylin and calcitonin strongly enhance the susceptibility of rat hippocampal neurons to excitatory amino acids in vivo
  651. Protective action of amylin on ulcer model of pylorus ligation
  652. Postpartum evaluation of amylin secretion in gestational diabetes mellitus
  653. Effect of amylin on insulin secretion in rat pancreatic islets and its mechanism
  654. Sustained Glucose-Lowering and Gastric-Emptying Effects of Amylin Agonism in Rats
  655. Effects of Pramlintide (Amylin Agonist) in Type 1 Diabetes are not mediated by GLP-1 (7-36) amide
  656. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin transgenic mice
  657. Amylin, 8. L protein Introduction
  658. The effect of different glucose endovenous administrations on amylin and insulin blood concentration in healthy subjects.
  659. Protective antiulcer and analgetic actions of amylin-islet pancreatic polypeptide
  660. Serum amylin correlates with delayed gastric emptying in critically ill children
  661. If You Poison Us Do We Not Die-A Critical Analysis of the Legality of Poison Puts in the Wake of San Antonio Fire & Police Pension Fund v. Amylin, Inc.
  662. The Roles of Amylin in the Periphery
  663. Pharmacology of amylin action
  664. Good news for Amylin
  665. Zirkadiane anorektische Effekte von peripher verabreichtem Amylin bei Ratten
  666. Amylin and its role in metabolic control
  667. Functional study of amylin and regulation of amylin receptor
  668. Environmental effects on conformational diseases. Reactive oxygen species and membrane interactions with prion, amylin and their peptide fragments
  669. mRNA profiling of pancreatic islets isolated from persistent hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) reveals low amylin gene expression
  670. Aspirations for amylin-will they be realised?
  671. Peptide and protein structure in aqueous hexafluoroisopropanol:(I) Monomeric and beta-aggregate forms of human amylin.(II) Cold denaturation of alpha …
  672. The Effect of Amylin on Insulin Action in Cultured Cells
  673. Amylin peptides
  674. Study of serum amylin level among Egyptian obese patients
  675. Role of amylin in the regulation of energy metabolism in health and disease
  676. Effect of Ensure® overfeeding on the anorectic effect of amylin
  677. Acute pancreatitis: epidemiology and relationship to amylin
  678. Characterisation of human amylin transgenic mice
  679. Amyloidogenesis in type II diabetes: aggregation and stability of human amylin
  680. Molecular mechanism of human amylin-mediated cytotoxicity
  681. AMYLIN: A PEPTIDE REGULATING FAT STORES?
  682. Variability of Amylin Gene in Korean Subjects
  683. Ser2001y Mutation of Amylin in Essential Hypertensives
  684. Amylin is a Substrate for Insulin-Degrading Enzyme (IDE)
  685. Treatment of diabetes mellitus with amylin agonists
  686. Treatment of diabetes mellitus with amylin agonists
  687. The effect of amylin on glucose metabolism in skeletal muscle
  688. Spectroscopic Characterization of PEG-Amylin Derivatives
  689. Amylin Pharmaceuticals, Inc., San Diego, CA
  690. Amylin Pharmaceuticals: Diabetes and Beyond
  691. Amylin–a partner hormone to insulin
  692. Studies of the amylin signalling pathway in skeletal muscle with respect to carbohydrate metabolism
  693. Central modulation of the feeding response to amylin by leptin and insulin.
  694. Amylin: Another beta-cell killer.
  695. Amyloid formation by human amylin
  696. Transcription of the amylin gene in newborn dogs
  697. Amylin Detection on a Miniature Optical Fiber Sensor
  698. IN VITRO zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA AUTORADIOGRAPHIC LOCALIZATION OF AMYLIN BINDING SITES IN RAT …
  699. Clinical Characteristics of S20G Mutation of Amylin Gene in Korean Type 2 Diabetic Patients.
  700. Structural analysis of amylin and its analogs by NMR spectroscopy
  701. Spontaneous Diabetes in Hemizygous Human-amylin Transgenic Mice without Islet Amyloid Formation
  702. Augmenting With Amylin: Hormone slows bone breakdown
  703. Immunocytochemical Expression of Amylin in Pancreatic Islets of Man, Rabbit and Guinea Pig
  704. Amylin and insulin resistance in diabetic patients with liver cirrhosis
  705. Central amylin causes more potent anorexigenic effects in chicks selected for low rather than high body weight
  706. Amylin stimulates plasma renin activity by a mechanism distinct from that of CGRP.
  707. Polymorphism and assembly dynamics of amylin fibrils
  708. Ya Huang, Amylin Pharmaceuticals, Inc., San Diego, CA
  709. Experimental study of amylin-induced functional damage to rat pancreatic islet cells in vitro
  710. Influence of amylin on apoptosis of human pancreatic islet?-cells and its molecular mechanism
  711. The influence of amylin on glucose metabolism in mouse hepatocytes is independent of cAMP
  712. Study of serum amylin in liver cirrhosis with diabetes mellitus
  713. The effects of human amylin over-expression in a transgenic model of diabetes mellitus
  714. Effect of islet amyloid polypeptide (Amylin) on glucose metabolism and secretion of insulin in the rats
  715. Effects of amylin on bone development and egg production in hens
  716. Activation of ghrelin and amylin in the subfornical organ in rat slice preparations
  717. Islet human amylin oligomer formation is differentially correlated with β-cell death and diabetes onset between homozygous and hemizygous human amylin …
  718. Amylin sensitivity and secretion following diet-induced obesity in rats
  719. Characterisation of calcitonin generelated peptide (CGRP) and amylin receptors
  720. Islet amyloid polypeptide (IAPP, amylin) in dexamethasone treated rats
  721. Human IAPP/amylin overproducing transgenic mice: Characterization of an animal model to study the role of IAPP in the pathogenesis of Type 2 diabetes
  722. calcitonin-gene-related peptide and amylin
  723. Amylin Levels Decrease 1 Month After Roux–en-Y Gastric Bypass Surgery in Patients with Type 2 Diabetes.
  724. Study of factors affecting amylin fibril formation and the characterization of a protein which prevents amyloidogenesis
  725. Identification and Characterization of an Insulin Based Inhibitor of Amylin and Aβ40 Amyloid Formation
  726. Lack of Association between the S20G Missense Mutation of Amylin Gene and Essential Hypertension in Korean Population
  727. Calcitonin/Amylin Receptors and Ramps
  728. Calcitonin, amylin, CGRP and adrenomedullinbph_501_14 30.. 31
  729. Human and Rat Amylin: Syntheses, Structures and Binding Sites
  730. Central amylin decreases appetite and total food transit rate in 4‐day post hatch chicks
  731. Amylin and Neuromedin U-Two Novel Regulatory Peptides of the Gastroenteropancreatic System
  732. Combination therapy with amylin and PYY (3–36) in diet-induced obese rats: A response surface analysis.
  733. Effect of amylin on biomechanical properties of the femur in glucocorticoid-induced osteoporosis rats
  734. No Association of the S20g Mutation of Amylin Gene with Insulin Secretion, Insulin Sensitivity, and Diabetes Mellitus in Taiwanese
  735. Amylin Gene Sequence of the Amyloidogenic Region in the Velvet Monkey (Chlorocebus aethiops).
  736. Selection and preliminary identification of human Fab fragement antibody against amylin from phage antibody library.
  737. Calcitonin, amylin, CGRP and adrenomedullin
  738. Receptors for adrenomedullin, amylin, and parathyroid hormone: identification, pharmacological characterization and cellular mechanisms
  739. The mechanism of death evoked by human amylin in pancreatic islet B cells
  740. Effects of oral glucose ingestion on plasma amylin concentration in diabetic and nondiabetic humans.
  741. Collapse Of Rat And Human Amylin From Nanosecond-resolved Intramolecular Contact Formation
  742. New regulatory peptides in rat stomach secretion (amylin, PGP, semax)
  743. Calcitonin gene-related peptide (CGRP), amylin
  744. Involvement of amylin and leptin in early developmental programming of brain pathways controlling energy balance and body weight
  745. Bombesin but not amylin blocks the orexigenic effect of peripheral ghrelin
  746. Effects of amylin on bone minernal density and structure parameters of bone tissue in glucocorticoid-induced osteoporosis rats
  747. Dark-Cycle Feeding and Meal Pattern Analysis in Rats Following Peripheral Administration of the Novel Amylin-Mimetic Peptide Davalintide
  748. … Mobilizes [Ca2+]i and Stimulates the Release of Pancreatic Digestive Enzymes From Rat Acinar AR42J Cells: Evidence for an Exclusive Receptor System of Amylin
  749. Role of Amylin and Calcitonin-Gene-Related Peptide (CGRP) in the Control of Food Intake
  750. Alain D. Baron has joined Amylin Pharmaceuticals (San Diego, CA) as vice president, clinical research. Dr. Baron joins the company from Indiana University School of …
  751. Amylin Enhances Glucose Stimulated Insulin Release From Neonatal Rat Pancreatic Islets.
  752. The effects of amylin on the islet beta-cells voltage-gated L-calcium channels in rats
  753. Acute Experimental Pancreatitis in Rats Is Ameliorated by Treatment with Pramlintide, a Synthetic Analogue of the β-Cell Hormone Amylin: 189
  754. Neurotrophic effects of amylin during development of brainstem projections involved in energy homeostasis
  755. Cardiovascular and metabolic responses to peripheral leptin infusion in rats: Role of amylin in leptin sensitivity
  756. Fas-associated death receptor signaling evoked by human amylin in islet β-cellsd
  757. Co-secretion of amylin and insulin from a clonal mouse β-cell line: modulation by nutrient secretagogues, somatostatin and a somatostatin analogue
  758. Aggregation of Amylin in type II diabetes: Molecular recognition elements in islet amyloid assembly and functional inhibition
  759. Potent combination of amylin and leptin reduces food intake, blood pressure, and orexigenic neuropeptides in obese FBNF1 rats
  760. Amylin excites a subset of proopiomelanocortin (POMC) neurons in the arcuate nucleus (ARC) via enhancing the excitatory glutamatergic synaptic inputs
  761. Solid state NMR investigations of lipid bilayers and biomembrane binding molecules: Dendrimers and amylin
  762. Fas-associated Death Receptor Signalling Evoked by Human Amylin in Islet B-cells
  763. Human Amylin-induced Apoptosis of RINm5F Islet β-cells is Associated with Increased Reactive Oxygen Species, but not Nitric Oxide or Zinc Ion
  764. Peptide fragments from amylin, calcitonin, and alpha-lactalbumin as models of protein aggregation and protein folding
  765. 3P-047 Kinetic association of amylin fibrils and lipid vesicles (The 46th Annual Meeting of the Biophysical Society of Japan)
  766. … K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C: Progressive reduction in body weight after treatment with the amylin analog pramlintide in …
  767. … chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP supress misfolding and formation of beta-sheet-containing aggregates by human amylin: apotential role for …
  768. … -1 LOWERS mRNA LEVEL OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK) GENE, BUT DOES NOT SUPPRESS AMYLIN GENE EXPRESSION IN …
  769. Characterization of the amyloidogenic subunits Aβ 1-4 0, Aβ 1-4 2, Aβ 1-4 0 (Dutch) and amylin: heparin-binding properties and multiple effects of Congo red.
  770. Changes Occurring in the Concentration of Insulin-like Growth Factor-1, Amylin and in Insulin in Relation to Diabetes Melltius
  771. Amylin: pharmacology, physiology, and clinical potential
  772. Creating the amylin story
  773. Control of energy homeostasis by amylin
  774. pH dependence of amylin fibrillization
  775. Amylin deposition in the brain: a second amyloid in Alzheimer disease?
  776. Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development
  777. Primer on pramlintide, an amylin analog
  778. Amyloidogenesis of the amylin analogue pramlintide
  779. Role of amylin in type 1 and type 2 diabetes
  780. Development of cagrilintide, a long-acting amylin analogue
  781. Amylin brain circuitry
  782. Mechanism of amylin fibrillization enhancement by heparin
  783. A structural basis for amylin receptor phenotype
  784. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes
  785. Amylin–Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
  786. Role and cytotoxicity of amylin and protection of pancreatic islet β-cells from amylin cytotoxicity
  787. Amylin at the interface between metabolic and neurodegenerative disorders
  788. Amylin as a potential link between type 2 diabetes and alzheimer disease
  789. Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin
  790. Copper (II)–human amylin complex protects pancreatic cells from amylin toxicity
  791. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer’s disease pathogenesis and cognition
  792. Amylin as a future obesity treatment
  793. The interaction of amylin with other hormones in the control of eating
  794. Neuroendocrine hormone amylin in diabetes
  795. Amylin modulates the mesolimbic dopamine system to control energy balance
  796. Interaction of amylin species with transition metals and membranes
  797. Amylin and its analogs: a friend or foe for the treatment of Alzheimer’s disease?
  798. The role of copper(ii) in the aggregation of human amylin
  799. Rutin inhibits amylin-induced neurocytotoxicity and oxidative stress
  800. Amylin analog pramlintide induces migraine‐like attacks in patients
  801. Amylin uncovered: a review on the polypeptide responsible for type II diabetes
  802. Activity of Pramlintide, Rat and Human Amylin but not Aβ1–42 at Human Amylin Receptors
  803. Effects of amylin on eating and adiposity
  804. 2DIR spectroscopy of human amylin fibrils reflects stable β-sheet structure
  805. Copper (II) and amylin analogues: A complicated relationship
  806. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor
  807. Amylin-mediated control of glycemia, energy balance, and cognition
  808. Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrils
  809. Amylin acts in the central nervous system to increase sympathetic nerve activity
  810. Hypothalamic amylin acts in concert with leptin to regulate food intake
  811. Amylin is a novel neuropeptide with potential maternal functions in the rat
  812. Mechanistic perspective and functional activity of insulin in amylin aggregation
  813. Amylin: what might be its role in Alzheimer’s disease and how could this affect therapy?
  814. Amylin antibodies frequently display cross-reactivity with CGRP: characterization of eight amylin antibodies
  815. Amylin activates distributed CNS nuclei to control energy balance
  816. β-Amyloid protein (Aβ) and human amylin regulation of apoptotic genes occurs through the amylin receptor
  817. Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin
  818. Human amylin: from pathology to physiology and pharmacology
  819. Amylin receptor ligands reduce the pathological cascade of Alzheimer’s disease
  820. Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly
  821. Monoconjugation of human amylin with methylpolyethyleneglycol
  822. Long-acting amylin analogues for the management of obesity
  823. Molecular signature for receptor engagement in the metabolic peptide hormone amylin
  824. Interictal amylin levels in chronic migraine patients: A case-control study
  825. The association of circulating amylin with β‐amyloid in familial Alzheimer’s disease
  826. Mediators of amylin action in metabolic control
  827. Amylin signaling in diabetes and Alzheimer’s disease: therapy or pathology?
  828. Peripheral insulin and amylin levels in Parkinson’s disease
  829. Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake
  830. Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling
  831. Secondary structure of rat and human amylin across force fields
  832. Effect of proline mutations on the monomer conformations of amylin
  833. Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells
  834. Amylin alters human brain pericyte viability and NG2 expression
  835. Lessons from two prevalent amyloidoses—what amylin and Aβ have in common
  836. d-Retro Inverso Amylin and the Stability of Amylin Fibrils
  837. Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol
  838. Deamidation accelerates amyloid formation and alters amylin fiber structure
  839. Ion mobility spectrometry–mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors
  840. Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice
  841. Amylin receptor: a common pathophysiological target in Alzheimer’s disease and diabetes mellitus
  842. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of …
  843. Preparation and characterization of PEGylated amylin
  844. Amylin-Calcitonin receptor signaling in the medial preoptic area mediates affiliative social behaviors in female mice
  845. Amylin and leptin: co-regulators of energy homeostasis and neuronal development
  846. Regulation of the assembly and amyloid aggregation of murine amylin by zinc
  847. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?
  848. Amylin receptor components and the leptin receptor are co‐expressed in single rat area postrema neurons
  849. Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior
  850. Molecular mechanisms of amylin turnover, misfolding and toxicity in the pancreas
  851. On the structure of the copper–amylin complex
  852. Rodent models of leptin receptor deficiency are less sensitive to amylin
  853. In Silico Cross Seeding of Aβ and Amylin Fibril-like Oligomers
  854. Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways
  855. Amylin in Alzheimer’s disease: Pathological peptide or potential treatment?
  856. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor
  857. A cationic polymethacrylate-copolymer acts as an agonist for β-amyloid and an antagonist for amylin fibrillation
  858. Conformational distribution and α-helix to β-sheet transition of human amylin fragment dimer
  859. Protein aggregates and proteostasis in aging: Amylin and β-cell function
  860. Circulating differentially methylated amylin DNA as a biomarker of β-cell loss in type 1 diabetes
  861. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
  862. Probing ion channel activity of human islet amyloid polypeptide (amylin)
  863. Amylin receptor: a potential therapeutic target for Alzheimer’s disease
  864. Ionic strength effects on amyloid formation by amylin are a complicated interplay among Debye screening, ion selectivity, and Hofmeister effects
  865. IAPP/amylin and β-cell failure: Implication of the risk factors of type 2 diabetes
  866. CGRP, amylin, immunology, and headache medicine
  867. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose
  868. Amylin amyloid inhibition by flavonoid baicalein: key roles of its vicinal dihydroxyl groups of the catechol moiety
  869. Molecular insights into the oligomerization dynamics and conformations of amyloidogenic and non-amyloidogenic amylin from discrete molecular dynamics …
  870. Amylin–Aβ oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer’s disease
  871. Inhibition of human amylin aggregation and cellular toxicity by lipoic acid and ascorbic acid
  872. Structure and thermodynamics of amylin dimer studied by Hamiltonian-temperature replica exchange molecular dynamics simulations
  873. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model
  874. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans
  875. Long-acting amylin analogue for weight reduction
  876. Genistein: a dual inhibitor of both amyloid β and human islet amylin peptides
  877. The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping
  878. Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas
  879. Receptor-mediated toxicity of human amylin fragment aggregated by short-and long-term incubations with copper ions
  880. Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer’s disease mouse model
  881. Orientations of residues along the β-arch of self-assembled amylin fibril-like structures lead to polymorphism
  882. Identification of key interactions in the initial self-assembly of amylin in a membrane environment
  883. Fractal self-assembly and aggregation of human amylin
  884. Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation
  885. Molecular simulations indicate marked differences in the structure of amylin mutants, correlated with known aggregation propensity
  886. Amyloidogenicity, cytotoxicity, and receptor activity of bovine amylin: implications for xenobiotic transplantation and the design of nontoxic amylin variants
  887. Activation of amylin receptors attenuates alcohol‐mediated behaviours in rodents
  888. Intraneuronal amylin deposition, peroxidative membrane injury and increased IL-1β synthesis in brains of Alzheimer’s disease patients with type-2 diabetes and in …
  889. Polymeric particles for the controlled release of human amylin
  890. GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
  891. TNF-α acutely upregulates amylin expression in murine pancreatic beta cells
  892. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology
  893. Association of plasma amylin concentration with Alzheimer disease and brain structure in older adults
  894. α-helix to β-hairpin transition of human amylin monomer
  895. Amylin selectively signals onto POMC neurons in the arcuate nucleus of the hypothalamus
  896. Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
  897. Heme bound amylin: spectroscopic characterization, reactivity, and relevance to type 2 diabetes
  898. Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat
  899. Human Amylin in the Presence of SARS-COV-2 Protein Fragments
  900. Amylin as a potential link between type 2 diabetes and Alzheimer disease
  901. Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake
  902. Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer’s disease
  903. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer’s disease
  904. Active-site environment of copper-bound human amylin relevant to type 2 diabetes
  905. Distributed amylin receptor signaling and its influence on motivated behavior
  906. Heterogeneous amylin fibril growth mechanisms imaged by total internal reflection fluorescence microscopy
  907. The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy
  908. Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
  909. Amylin acts in the lateral dorsal tegmental nucleus to regulate energy balance through gamma-aminobutyric acid signaling
  910. Associations of amylin with inflammatory markers and metabolic syndrome in apparently healthy Chinese
  911. Benzbromarone, quercetin, and folic acid inhibit amylin aggregation
  912. Amylin receptor signaling in the nucleus accumbens negatively modulates μ-opioid-driven feeding
  913. Positive association between plasma amylin and cognition in a homebound elderly population
  914. Change of plasma amylin after bariatric surgery challenged by oral glucose is associated with remission of type 2 diabetes mellitus
  915. A new polymorphism of human amylin fibrils with similar protofilaments and a conserved core
  916. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats
  917. Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
  918. An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder
  919. An amylin analog used as a challenge test for Alzheimer’s disease
  920. An amylin and calcitonin receptor agonist modulates alcohol behaviors by acting on reward-related areas in the brain
  921. Distinct internalization pathways of human amylin monomers and its cytotoxic oligomers in pancreatic cells
  922. Inter-species cross-seeding: stability and assembly of rat-human amylin aggregates
  923. Systemic and central amylin, amylin receptor signaling, and their physiological and pathophysiological roles in metabolism
  924. Neuroprotective effects of the amylin analog, pramlintide, on Alzheimer’s disease are associated with oxidative stress regulation mechanisms
  925. The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet β cells
  926. Amylin Dyshomeostasis Hypothesis: Small Vessel–Type Ischemic Stroke in the Setting of Type-2 Diabetes
  927. Does receptor balance matter?–Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic …
  928. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli
  929. Fasting levels of insulin and amylin after acute pancreatitis are associated with pro-inflammatory cytokines
  930. Inhibition of human amylin fibril formation by insulin-mimetic vanadium complexes
  931. Calcitonin and amylin receptor peptide interaction mechanisms: insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by …
  932. Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice
  933. Rosmarinic acid potently detoxifies amylin amyloid and ameliorates diabetic pathology in a transgenic rat model of type 2 diabetes
  934. Disaggregation of amylin aggregate by novel conformationally restricted aminobenzoic acid containing α/β and α/γ hybrid peptidomimetics
  935. Characterizing the assembly behaviors of human amylin: a perspective derived from C-terminal variants
  936. Copper (II) complexes of rat amylin fragments
  937. Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity
  938. Amylin, bariatric surgery, and type 2 diabetes mellitus
  939. Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries
  940. High-fat diet increases amylin accumulation in the hippocampus and accelerates brain aging in hIAPP transgenic mice
  941. Rapid assessment of human amylin aggregation and its inhibition by copper (II) ions by laser ablation electrospray ionization mass spectrometry with ion mobility …
  942. Analysis of amylin consensus sequences suggests that human amylin is not optimized to minimize amyloid formation and provides clues to factors that modulate …
  943. Date palm (Phoenix dactylifera L.) fruit’s polyphenols as potential inhibitors for human amylin fibril formation and toxicity in type 2 diabetes
  944. Olive component oleuropein promotes β-cell insulin secretion and protects β-cells from amylin amyloid-induced cytotoxicity
  945. Neuroprotective effects of amylin analogues on Alzheimer’s disease pathogenesis and cognition
  946. Anti-aggregation effect of carbon quantum dots on diabetogenic and beta-cell cytotoxic amylin and beta amyloid heterocomplexes
  947. Insight into a new binding site of zinc ions in fibrillar amylin
  948. Mutations and seeding of amylin fibril-like oligomers
  949. α-CGRP disrupts amylin fibrillization and regulates insulin secretion: Implications on diabetes and migraine
  950. Amyloidogenesis of feline amylin and plasma levels in cats with diabetes mellitus or pancreatitis
  951. Thermodynamic surprises of Cu (II)–amylin analogue complexes in membrane mimicking solutions
  952. High-speed atomic force microscopy reveals the structural dynamics of the amyloid-β and amylin aggregation pathways
  953. Varicella-zoster virus infection of primary human spinal astrocytes produces intracellular amylin, amyloid-β, and an amyloidogenic extracellular environment
  954. Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists
  955. Human amylin aggregates release within exosomes as a protective mechanism in pancreatic β cells: Pancreatic β-hippocampal cell communication
  956. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
  957. Undercover toxic ménage à trois of Amylin, Copper (II) and Metformin in human embryonic kidney cells
  958. IAPP/amylin deposition, which is correlated with expressions of ASC and IL-1β in β-cells of Langerhans’ islets, directly initiates NLRP3 inflammasome activation
  959. The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy
  960. Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure–activity relationships for amylin receptor agonism
  961. Non-selective ion channel activity of polymorphic human islet amyloid polypeptide (amylin) double channels
  962. The role of leptin in the sporadic form of Alzheimer’s disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin
  963. Molecular mechanisms of the bindings between non-amyloid β component oligomers and amylin oligomers
  964. Amylin/Calcitonin receptor–mediated signaling in POMC neurons influences energy balance and locomotor activity in chow-fed male mice
  965. Effects of forcefield and sampling method in all-atom simulations of inherently disordered proteins: Application to conformational preferences of human amylin
  966. Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes
  967. Amylin and amylin receptors in Alzheimer’s disease
  968. ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 …
  969. A novel dual amylin and calcitonin receptor agonist, KBP‐089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference
  970. The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy
  971. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
  972. Automated detection of squint as a sensitive assay of sex-dependent calcitonin gene–related peptide and amylin-induced pain in mice
  973. The removal of disulfide bonds in amylin oligomers leads to the conformational change of the ‘native’amylin oligomers
  974. A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1–37
  975. Amylin induces hypoglycemia in mice
  976. Synthesis and evaluation of disulfide bond mimetics of amylin-(1–8) as agents to treat osteoporosis
  977. Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide
  978. Stepwise oligomerization of murine amylin and assembly of amyloid fibrils
  979. Amide proton solvent protection in amylin fibrils probed by quenched hydrogen exchange NMR
  980. Amylin enhances amyloid-β peptide brain to blood efflux across the blood-brain barrier
  981. Genetic depletion of amylin/calcitonin receptors improves memory and learning in transgenic Alzheimer’s disease mouse models
  982. Hypoglycemia attenuates acute amylin-induced reduction of food intake in male rats
  983. Effect of Zn 2+ ions on the assembly of amylin oligomers: insight into the molecular mechanisms
  984. Pramlintide antagonizes beta amyloid (Aβ)-and human amylin-induced depression of hippocampal long-term potentiation
  985. Inhibition of human amylin aggregation by Flavonoid Chrysin: An in-silico and in-vitro approach
  986. Amylin and diabetic cardiomyopathy–amylin-induced sarcolemmal Ca2+ leak is independent of diabetic remodeling of myocardium
  987. Charge-based inhibitors of amylin fibrillization and toxicity
  988. The dual amylin‐and calcitonin‐receptor agonist KBP‐042 increases insulin sensitivity and induces weight loss in rats with obesity
  989. Amylin pharmacology in Alzheimer’s disease pathogenesis and treatment
  990. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease
  991. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin–physiology and pharmacology
  992. The satiating hormone amylin enhances neurogenesis in the area postrema of adult rats
  993. Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele
  994. Charge effects at nano-bio interfaces: a model of charged gold nanoclusters on amylin fibrillation
  995. Amylin and leptin interaction: role during pregnancy, lactation and neonatal development
  996. Inhibition of human islet amyloid polypeptide or amylin aggregation by two manganese-salen derivatives
  997. The role of two natural flavonoids on human amylin aggregation
  998. Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure
  999. Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes
  1000. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 …
  1001. Molecular dynamics simulation study on the molecular structures of the amylin fibril models
  1002. Slow internal dynamics and charge expansion in the disordered protein CGRP: A comparison with amylin
  1003. Structural modulation of human amylin protofilaments by naturally occurring mutations
  1004. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines
  1005. Amylin, a peptide expressed by nociceptors, modulates chronic neuropathic pain
  1006. Silibinin ameliorates amylin-induced pancreatic β-cell apoptosis partly via upregulation of GLP-1R/PKA pathway
  1007. Activation of the amylin pathway modulates cocaine-induced activation of the mesolimbic dopamine system in male mice
  1008. Involvement of amylin and leptin in the development of projections from the area postrema to the nucleus of the solitary tract
  1009. Suppl 2: amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function
  1010. Role of cholesterol and phospholipids in amylin misfolding, aggregation and etiology of islet amyloidosis
  1011. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and …
  1012. Assembly behavior of amylin fragment hIAPP19-37 regulated by Au (III) complexes
  1013. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status
  1014. Computational modeling of amylin-induced calcium dysregulation in rat ventricular cardiomyocytes
  1015. Chiral effect at nano-bio interface: a model of chiral gold nanoparticle on amylin fibrillation
  1016. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice
  1017. Amylin may offer (more) help to treat postmenopausal obesity
  1018. Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat
  1019. Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood
  1020. Amylin receptor insensitivity impairs hypothalamic POMC neuron differentiation in the male offspring of maternal high-fat diet-fed mice
  1021. Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
  1022. Effects of sub-chronic amylin receptor activation on alcohol-induced locomotor stimulation and monoamine levels in mice
  1023. Role of mass spectrometry in the study of interactions between amylin and metal ions
  1024. Whole‐brain mapping of amylin‐induced neuronal activity in receptor activity–modifying protein 1/3 knockout mice
  1025. Sequence specificity of amylin-insulin interaction: a fragment-based insulin fibrillation inhibition study
  1026. Amylin Protein Expression in the Rat Brain and Neuro-2a Cells
  1027. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and …
  1028. Azadirachtin inhibits amyloid formation, disaggregates pre-formed fibrils and protects pancreatic β-cells from human islet amyloid polypeptide/amylin-induced …
  1029. Aggregation of amylin: Spectroscopic investigation
  1030. Salmon calcitonin exerts an antidepressant effect by activating amylin receptors
  1031. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state
  1032. Delayed response of amylin levels after an oral glucose challenge in children with Prader-Willi syndrome
  1033. Effects of a selective long‐acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats
  1034. Molecular interaction of an antagonistic amylin analog with the extracellular domain of receptor activity-modifying protein 2 assessed by fluorescence polarization
  1035. Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons
  1036. Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists
  1037. Sub-toxic human amylin fragment concentrations promote the survival and proliferation of SH-SY5Y cells via the release of VEGF and HSPB5 from endothelial RBE4 …
  1038. Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
  1039. Influence of human amylin on the membrane stability of rat primary hippocampal neurons
  1040. Amylin deposition activates HIF1α and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates
  1041. Heterogeneous triangular structures of human islet amyloid polypeptide (amylin) with internal hydrophobic cavity and external wrapping morphology reveal the …
  1042. Amylin conjugation with methoxyl polyethyleneglycol
  1043. Proteasome regulates turnover of toxic human amylin in pancreatic cells
  1044. Combined amylin–leptin treatment lowers blood pressure and adiposity in lean and obese rats
  1045. How to blast osteoblasts? Novel dicarba analogues of amylin-(1–8) to treat osteoporosis
  1046. Zinc Interactions with a Soluble Mutated Rat Amylin to Mimic Whole Human Amylin: An Experimental and Simulation Approach to Understand Stoichiometry …
  1047. Amylin-induced downregulation of hippocampal neurogenesis is attenuated by leptin in a STAT3/AMPK/ERK-dependent manner in mice
  1048. Acute zoster plasma contains elevated amyloid, correlating with Aβ42 and amylin levels, and is amyloidogenic
  1049. Amylin–leptin coadministration stimulates central histaminergic signaling in rats
  1050. Active-site environment of Cu bound amyloid β and amylin peptides
  1051. Physico-chemical stability of co-formulation of PEGylated human amylin with insulin
  1052. Monitoring oligomer formation from self-aggregating amylin peptides using ESI-IMS-MS
  1053. … on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 …
  1054. A selective role for receptor activity‐modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body …
  1055. Quantification of protein aggregation rates and quenching effects of amylin–inhibitor complexes
  1056. Incretins, amylin and other gut‐brain axis hormones in children with coeliac disease
  1057. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats
  1058. MCP-1 upregulates amylin expression in murine pancreatic β cells through ERK/JNK-AP1 and NF-κB related signaling pathways independent of CCR2
  1059. Endogenous amylin and glucagon‐like peptide‐1 concentrations are not associated with gastric emptying in critical illness
  1060. Human islet amyloid polypeptide overexpression in INS-1E cells influences amylin oligomerization under ER stress and oxidative stress
  1061. Amylin in the insulin resistance of patients with rheumatoid arthritis
  1062. Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome
  1063. The dual amylin-and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes
  1064. Effect of two herbal polyphenol compounds on human amylin amyloid formation and destabilization
  1065. Copper ions induce dityrosine-linked dimers in human but not in murine islet amyloid polypeptide (IAPP/amylin)
  1066. Amylin blunts hyperphagia and reduces weight and fat gain during recovery in socially stressed rats
  1067. Probing amylin fibrillation at an early stage via a tetracysteine-recognising fluorophore
  1068. Amylin stimulates fatty acid esterification in 3T3-L1 adipocytes
  1069. Human amylin proteotoxicity impairs protein biosynthesis, and alters major cellular signaling pathways in the heart, brain and liver of humanized diabetic rat model in …
  1070. Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088: long-lasting improvement in food preference and body weight loss
  1071. The link between type 2 diabetes and neurodegeneration: roles for amyloid-β, amylin, and tau proteins
  1072. Pramlintide: an amylin analogue protects endothelial cells against oxidative stress through regulating oxidative markers and NF-κb expression
  1073. Bloodborne Pancreatic Amylin, a Therapeutic Target for Alzheimer’s Disease
  1074. Effect of agitation on the peptide fibrillization: Alzheimer’s amyloid‐β peptide 1‐42 but not amylin and insulin fibrils can grow under quiescent conditions
  1075. Heme bound amylin self-assembled monolayers on an Au electrode: an efficient bio-electrode for O 2 reduction to H 2 O
  1076. Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms
  1077. Novel amylin analogues reduce amyloid-β cross-seeding aggregation and neurotoxicity
  1078. Valsartan inhibits amylin-induced podocyte damage
  1079. Amylin, Aβ42, and amyloid in varicella Zoster virus vasculopathy cerebrospinal fluid and infected vascular cells
  1080. Plasma amylin and cognition in diabetes in the absence and the presence of insulin treatment
  1081. Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss
  1082. A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model
  1083. Serum preptin and amylin levels with respect to body mass index in polycystic ovary syndrome patients
  1084. Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction‐induced weight loss in rats
  1085. Relation between serum amylin level and epilepsy
  1086. BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats
  1087. Amperometric immunoassay for the obesity biomarker amylin using a screen printed carbon electrode functionalized with an electropolymerized carboxylated …
  1088. Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry
  1089. Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model
  1090. Deconvoluting the molecular control of binding and signaling at the amylin 3 receptor: RAMP3 alters signal propagation through extracellular loops of the calcitonin …
  1091. Noncompetitive affinity assays of glucagon and amylin using mirror-image aptamers as affinity probes
  1092. Mouse Microglial Calcitonin Receptor Knockout Impairs Hypothalamic Amylin Neuronal pSTAT3 Signaling but Lacks Major Metabolic Consequences
  1093. Effects of amylin on food intake and body weight via sympathetic innervation of the interscapular brown adipose tissue
  1094. The association between renal accumulation of pancreatic amyloid-forming amylin and renal hypoxia
  1095. Differential effect of amylin on endothelial-dependent vasodilation in mesenteric arteries from control and insulin resistant rats
  1096. First-phase insulin and amylin after bariatric surgery: a prospective randomized trial on patients with insulin resistance or diabetes after gastric bypass or …
  1097. Amylin level and gastric emptying in obese children: before and after weight loss
  1098. Comment on Yoo et al. Amylin Protein Expression in the Rat Brain and Neuro-2a Cells. Int. J. Mol. Sci. 2022, 23, 4348
  1099. Inhibition of human amylin amyloidogenesis by human amylin-fragment peptides: Exploring the effects of serine residues and oligomerization upon inhibitory potency
  1100. Full length amylin oligomer aggregation: insights from molecular dynamics simulations and implications for design of aggregation inhibitors
  1101. Complete characterization of the mutation landscape reveals the effect on amylin stability and amyloidogenicity
  1102. Melatonin influences the expression and oligomerization of amylin in rat INS-1E cells
  1103. Identification, tissue distribution, and anorexigenic effect of amylin in Siberian sturgeon (Acipenser baeri)
  1104. Serum preptin and amylin values in psoriasis vulgaris and Behçet’s patients
  1105. Antipsychotic-like actions of the satiety peptide, amylin, in ventral striatal regions marked by overlapping calcitonin receptor and RAMP-1 gene expression
  1106. Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer’s Disease in a Mouse Model
  1107. The amylin peptide implicated in type 2 diabetes stimulates copper-mediated carbonyl group and ascorbate radical formation
  1108. The dual amylin and calcitonin receptor agonist, KBP-066, induces an equally potent weight loss across a broad dose range while higher doses may further improve …
  1109. Cyclic N-terminal loop of amylin forms non amyloid fibers
  1110. The increase in the number of amylin neurons in the medial preoptic area throughout the lactational period and its relationship with melanin-concentrating hormone
  1111. The central anorexigenic mechanism of amylin in Japanese quail (Coturnix japonica) involves pro-opiomelanocortin, calcitonin receptor, and the arcuate nucleus of …
  1112. Silibinin protects rat pancreatic β‐cell through up‐regulation of estrogen receptors’ signaling against amylin‐ or Aβ1–42‐induced reactive oxygen species/reactive …
  1113. Glycomacropeptide Impacts Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, and the Fecal Microbiome in Obese Postmenopausal …
  1114. Peptide conjugates of benzene carboxylic acids as agonists and antagonists of amylin aggregation
  1115. In silico comparative study of human and porcine amylin
  1116. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1
  1117. Palatable food access impacts expression of amylin receptor components in the mesocorticolimbic system
  1118. Amylin regulates testosterone levels via steroidogenesis-related enzymes in the central nervous system of male mice
  1119. Amylin serum levels are upregulated in patients with systemic lupus erythematosus.
  1120. Evolutionary adaptation and amyloid formation: does the reduced amyloidogenicity and cytotoxicity of ursine amylin contribute to the metabolic adaption of bears and …
  1121. … of amyloid aggregates stabilized by main chain H-bond instead of the steric zipper: molecular dynamics study of the amyloidogenic segment of amylin wild-type and …
  1122. Amylin in vasodilation, energy expenditure and inflammation
  1123. The dye SYPRO orange binds to amylin amyloid fibrils but not pre‐fibrillar intermediates
  1124. Quantitative, high-throughput assays for proteolytic degradation of amylin
  1125. Apoptosis signal regulating kinase-1 and NADPH oxidase mediate human amylin evoked redox stress and apoptosis in pancreatic beta-cells
  1126. Human amylin induces CD4+ Foxp3+ regulatory T cells in the protection from autoimmune diabetes
  1127. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
  1128. Understanding the mechanism of amylin aggregation: From identifying crucial segments to tracing dominant sequential events to modeling potential aggregation …
  1129. Analysis of prairie vole amylin reveals the importance of the N-terminus and residue 22 in amyloidogenicity and cytotoxicity
  1130. Development of 99mTc-Labeled Pyridyl Benzofuran Derivatives To Detect Pancreatic Amylin in Islet Amyloid Model Mice
  1131. Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS
  1132. Synthesis and evaluation of novel two-photon fluorescence probes for in vivo imaging of amylin aggregates in the pancreas
  1133. Diabetes-related amylin dyshomeostasis: a contributing factor to cerebrovascular pathology and dementia
  1134. Effects of amylin on egg quality traits of hens during the early laying period
  1135. Binding orientations and lipid interactions of human amylin at zwitterionic and anionic lipid bilayers
  1136. Intrathecal amylin and salmon calcitonin affect formalin induced c-fos expression in the spinal cord of rats
  1137. Effects of amylin against amyloid-β-induced tauopathy and synapse loss in primary neurons
  1138. Structural and thermodynamical properties of early human amylin oligomers using replica exchange molecular dynamics: mutation effect of three key residues F15 …
  1139. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
  1140. Metabolic regulator IAPP (Amylin) is required for BRAF and RAS oncogene-induced senescence
  1141. Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC–MS/MS
  1142. Complex formation of nickel (ii) and zinc (ii) ions with peptide fragments of rat amylin
  1143. An inducible model of human amylin overexpression reveals diverse transcriptional changes
  1144. Amylin modulates the formalin‐induced tonic pain behaviours in rats
  1145. The BDNF protein and its cognate mRNAs in the rat spinal cord during amylin-induced reversal of morphine tolerance
  1146. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm
  1147. Inhibition of amylin fibril formation and protection of islet β-cells by medicinal plants
  1148. Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
  1149. Amylin ve glukoz homeostazisi üzerine etkileri
  1150. Potentiometric and spectroscopic studies on the copper (II) complexes of rat amylin fragments. The anchoring ability of specific non-coordinating side chains
  1151. The toxic nature of murine amylin and the immune responsivity of pancreatic islet to conformational antibody in mice
  1152. Role of amylin and its receptors in neurodegeneration
  1153. Facilitatory and inhibitory role of central amylin administration in the regulation of the gonadotropin-releasing hormone pulse generator activity in goats
  1154. Coordination of Zn 2+ and Cu 2+ to the membrane disrupting fragment of amylin
  1155. Amylin analogs for the treatment of diabetes mellitus
  1156. … dye brilliant blue G is only moderately effective at inhibiting amyloid formation by human amylin or at disaggregating amylin amyloid fibrils, but interferes with …
  1157. Molecular confinement of human amylin in lipidic nanoparticles
  1158. Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation
  1159. Medicinal plants support the amylin-suppressed viability of islet β-cells
  1160. Structural effects driven by rare point mutations in amylin hormone, the type II diabetes-associated peptide
  1161. GLP-1 and amylin in the treatment of obesity
  1162. Conformational tuning of Amylin by charged styrene-maleic-acid copolymers
  1163. Ion‐Transfer Electrochemistry of Rat Amylin at the Water–Organogel Microinterface Array and Its Selective Detection in a Protein Mixture
  1164. Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in the rat embryonic spinal cells
  1165. Asn‐linked N–acetylglucosamine of the amylin receptor 2 extracellular domain enhances peptide ligand affinity
  1166. Assay development and multivariate scoring for high-content discovery of chemoprotectants of endoplasmic-reticulum-stress-mediated amylin-induced cytotoxicity in …
  1167. Structural Insights into the Polymorphism of Self‐Assembled Amylin Oligomers
  1168. Melanocortin 4 receptor–mediated effects of amylin on thermogenesis and regulation of food intake
  1169. Peripherally administered amylin inhibits stress-like behaviors and enhances cognitive performance
  1170. The Fluorescent Dye 1, 6-Diphenyl-1, 3, 5-hexatriene Binds to Amyloid Fibrils Formed by Human Amylin and Provides a New Probe of Amylin Amyloid Kinetics
  1171. Extracellular vesicles enriched with amylin receptor are cytoprotective against the Aß toxicity in vitro
  1172. Cyanidin-3-O-Glucoside improves the viability of human islet cells treated with amylin or Aβ1-42 in vitro
  1173. Endogenous amylin contributes to birth of microglial cells in arcuate nucleus of hypothalamus and area postrema during fetal development
  1174. The influence of amylin on the bile acid spectrum in rats
  1175. Preliminary examination of insulin and amylin levels in women with purging disorder
  1176. Inhibition of amyloid formation of amyloid β (1–42), amylin and insulin by 1, 5-diazacyclooctanes, a spermine-acrolein conjugate
  1177. Development of novel PET imaging probes for detection of amylin aggregates in the pancreas
  1178. Heterotropic modulation of amylin fibrillation by small molecules: Implications for formulative designs
  1179. Plasma levels of ghrelin and GLP-1, but not leptin or amylin, respond to a psychosocial stressor in women and men
  1180. The importance of understanding amylin signaling mechanisms for therapeutic development in the treatment of Alzheimer’s disease
  1181. A review of the efficacy and cardiovascular safety of amylin analogues
  1182. Novel potential regulators of maternal adaptations during lactation: tuberoinfundibular peptide 39 and amylin
  1183. Firing up brown fat with brain amylin
  1184. Amyloidogenicity and cytotoxicity of des-Lys-1 human amylin provides insight into amylin self-assembly and highlights the difficulties of defining amyloidogenicity
  1185. The correlation between amylin and insulin by treatment with 2-deoxy-D-glucose and/or mannose in rat insulinoma ins-1E cells
  1186. Preparation of uniformly 13C, 15N-labeled recombinant human amylin for solid-state NMR investigation
  1187. Neuroprotective Mechanisms of Amylin Receptor Activation, Not Antagonism, in the APP/PS1 Mouse Model of Alzheimer’s Disease
  1188. Development of peptide-based inhibitors of amylin aggregation employing aromatic and electrostatic repulsion
  1189. Investigation of the Effect of Pyrogallol on the Formation of Amylin Amyloid Fibrils as a Strategy for the Treatment of Type 2 Diabetic Patients: A Theoretical and …
  1190. Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid …
  1191. Modeling energy intake and body weight effects of a long-acting amylin analogue
  1192. … effect of Azadirachta excelsa leaves extract and quercetin treatment on the learning and memory impairments in relation with insulin and amylin levels in the …
  1193. Type‐2 Diabetes, Pancreatic Amylin, and Neuronal Metabolic Remodeling in Alzheimer’s Disease
  1194. The assessment value of pathological condition of serum adiponectin and amylin in primary osteoporosis and its correlation analysis with bone metabolism …
  1195. Amylin: new insight into pathogenesis, diagnosis, and prognosis of non-insulin-dependent diabetes-mellitus-related cardiomyopathy
  1196. Luminescent platforms for monitoring changes in the solubility of amylin and huntingtin in living cells
  1197. The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
  1198. Self-assembly of human amylin-derived peptides studied by atomic force microscopy and single molecule force spectroscopy
  1199. Novel radiogallium-labeled pyridyl benzofuran derivative for detection of amylin aggregates in pancreas
  1200. Synergistic long-range effects of mutations underlie aggregation propensities of amylin analogues
  1201. Correlations between endogen amylin hormone and some hormonal, biochemical and bone parameters in pullets
  1202. Brain Distribution and Sexually Dimorphic Expression of Amylin in Different Reproductive Stages of the Zebra Finch (Taeniopygia guttata) Suggest Roles of …
  1203. Intermittent High‐Fat Diet Intake Reduces Sensitivity to Intragastric Nutrient Infusion and Exogenous Amylin in Female Rats
  1204. … cytotoxicity assays of “aggregation‐prone” IAPP8–16 and its non‐amyloidogenic variants suggest its important role in fibrillogenesis and cytotoxicity of human amylin
  1205. Effects of heparin on amylin fibrillization
  1206. Functional coupling reactions of human amylin receptor and nicotinic acetylcholine receptors in rat brain neurons.
  1207. Amylin-like immunoreactivity in pancreatic X cells of the black-spotted frog Rana (Pelophylax) nigromaculata
  1208. Expression of Amylin and Preptinin Iraqi Patients with Type 2 Diabetes Mellitus
  1209. Concentration‐Dependent Interactions of Amphiphilic PiB Derivative Metal Complexes with Amyloid Peptides Aβ and Amylin
  1210. Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth
  1211. Amylin perturbs the organization of collagen network
  1212. Effect of eight weeks high-fat diet with endurance training on plasma levels of Amylin in male Wistar rats
  1213. Unambiguous characterization of PEGylation site on human amylin by two‐dimensional nuclear magnetic resonance spectroscopy
  1214. An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis
  1215. Microcanonical insights into the physicochemical stability of the coformulation of insulin with amylin analogues
  1216. Characterization of Novel 18F-Labeled Phenoxymethylpyridine Derivatives as Amylin Imaging Probes
  1217. Catechol-Containing Compounds are a Broad Class of Protein Aggregation Inhibitors: II. Rosmarinic Acid Potently Detoxifies Amylin Amyloid and Ameliorates Diabetic …
  1218. Preclinical Efficacy of NN1213, an Amylin Receptor Selective Analogue, in Animal Models of Obesity
  1219. Conformational tuning of amylin by charged SMA copolymers
  1220. Free energy simulations of amylin I26P mutation in a lipid bilayer
  1221. Characterising the signalling profiles of the calcitonin and amylin receptors
  1222. A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ 1–42, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing …
  1223. Involvement of amylin BH2S-connexin 43 signaling pathway in vascular dysfunction and enhanced ischemia–reperfusion-induced myocardial injury in diabetic rats
  1224. Ghrelin, amylin, gastric inhibitory peptide and cognition in middle-aged HIV-infected and uninfected women: the women’s interagency HIV study
  1225. Computational re-engineering of Amylin sequence with reduced amyloidogenic potential
  1226. Molecular Insights into the Role of Water in Early-stage Human Amylin Aggregation
  1227. Effects of Extract and Phenol Glycoside from Rose Petals on the Amylin Fibrils
  1228. Pramlintide: profile of an amylin analog
  1229. Author Correction: Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
  1230. Skin Capillary Amylin Deposition Resembles Brain Amylin Vasculopathy (S33. 003)
  1231. Amyloidogenic amylin deposits on red blood cells of stroke patients
  1232. Quantitative data describing the impact of the flavonol rutin on in-vivo blood-glucose and fluid-intake profiles, and survival of human-amylin transgenic mice
  1233. Novel insights into amylin aggregation
  1234. Unique inversion events of residues around the backbone in the turn domain of β-arches in amylin fibrils
  1235. Altered metabolic gene expression in the brain of a triprolyl-human amylin transgenic mouse model of type 2 diabetes
  1236. Study of ZN (II) effect on amylin aggregation
  1237. A case control study demonstrates an increase in plasma amylin associated with chronic migraine
  1238. Amyloid‐β removal from the brain is blocked by circulating amyloid‐forming amylin secreted by the pancreas
  1239. Correction to: IAPP/amylin and β‑cell failure: implication of the risk factors of type 2 diabetes
  1240. Anti-obesity effects of the novel long-acting amylin analogue ZP4982 in high-fat diet fed rats
  1241. Co-aggregation of alpha-synuclein with amylin (HIAPP) leads to an increased risk in type II diabetes patients for developing Parkinson’s disease
  1242. In vivo efficacy of human-derived anti-amylin antibodies in a transgenic mouse model of diabetes mellitus
  1243. Amylin oligomers stabilize membrane rafts
  1244. A direct fluorescence‐based technique for cellular localization of amylin
  1245. Non‐Aggregating Amylin Fragments as an Inhibitors of the Aggregation Process of Susceptible to Aggregation Fragments 18–22, 23–27, and 33–37 of Hormone
  1246. An electrospray ionization study on complexes of amylin with Cu (II) and Cu (I)
  1247. 092 Brain amylin accumulation in Parkinson’s disease is not driven by type 2 diabetes mellitus
  1248. Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model
  1249. Female mice exhibit a more sensitive automated squint response to pain induced by CGRP and amylin
  1250. Exploring expression of amylin and CGRP receptors in the rat brain
  1251. Molecular determinants of amylin receptor agonism
  1252. Amylin receptor agonism protects against metabolic side effects of acute olanzapine
  1253. Efficient optical plasmonic tweezer-controlled single-molecule SERS characterization of pH-dependent amylin species in aqueous milieus
  1254. Structure-based insight into development of selective and non-selective amylin and calcitonin receptor agonists
  1255. Serum preptin and amylin levels in acne vulgaris patients
  1256. Thermodynamic Surprises of Cu (II)-Amylin Complexes in Membrane Mimicking Solutions
  1257. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes
  1258. Association of amylin in the development of impaired fasting glucose and impaired glucose tolerance
  1259. Correlation of leptin, neuropeptide Y and amylin in childhood obesity
  1260. The Islet Amyloid Polypeptide hormone Amylin: Its function, effects and uses in medicine
  1261. Structural stability of diabetes-related amylin protofilaments: Applications to fibril design
  1262. Determination and significance of serum MPO and amylin in adult patients with OSAHS after short-range noninvasive positive pressure ventilation
  1263. Cyclic N terminal fragment of amylin forms non amyloid fibers: implications for intra-and inter-molecular interactions in amylin
  1264. The molecular mechanisms of Stress-Induced Amylin turnover in pancreatic Beta cell
  1265. Amylin
  1266. … Composition and Raft Domain Formation on the IAPP-Membrane Interaction: The Role of Cholesterol on the Inhibition of IAPP (Amylin) Fibrilization and the …
  1267. Correlation of helical propensity in amylin sequences with known aggregation propensity
  1268. Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention
  1269. Human amylin transgenic mice show elevated core body temperature and increased energy expenditure
  1270. Effects of The Anti-glucagon Treatment (Amylin) on Isolated Hearts Performance in Experimentally Induced Type II Diabetes in Rats
  1271. Physiological and pathophysiological role of islet amyloid polypeptide (IAPP, amylin)
  1272. Serum amylin level in Behçet’s disease and relation to parameters of metabolic syndrome and disease activity
  1273. Amylin under examination. Fibrillogenic polypeptide hormone of the pancreas
  1274. Effect of Vernonia amygdalina on the Serum Amylin and Insulin Levels of Alloxan-Induced Diabetic Rats
  1275. Ginger essential oil and citral ameliorate atherosclerosis via modulating TMAO and gut microbiota in ApoE−/− mice fed on Gubra amylin NASH diet with ʟ-carnitine
  1276. Plasma amylin concentration in suckling goat neonates and its relationship with C-reactive protein, selected biochemical and hormonal indicators
  1277. IDF21-0191 Plumbagin and Plumbagin amino acid ester conjugates inhibit amylin priori and post-priori
  1278. Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co-Morbidities
  1279. BZ043, a Novel Amylin Analog, in a Fixed Combination with Insulin Glargine—Nonclinical Results
  1280. In Silico cross seeding of A# and amylin fibril-like oligomers
  1281. Inhibition of human amylin aggregation: in silico and in vitro studies
  1282. Rosmarinic acid, a catechol‐containing natural product, potently inhibits amylin amyloidosis
  1283. Relation between serum amylin level and epilepsy
  1284. Hsp70 Delays Amyloid Aggregation of Amylin by Inhibiting Primary Nucleation
  1285. Analogues of amylin, alpha-glucosidase inhibitors and the digestive system in homeostasis regulation
  1286. Localization of amylin‐like immunoreactivity in the striped velvet gecko pancreas
  1287. Leptin and Amylin Influence the Excitability of Area Postrema Neurons, Possibly via cAMP‐Mediated Mechanisms
  1288. Effect Of Aqueous Alcoholic Extract Of Devil’s Claw On The Serum Levels Of Adiponectin, Agouti, Omentin, Amylin, Orexin A, Resistin, Chemerin, Ghrelin, Leptin, NPY …
  1289. Defining Sequence Determinants of Amylin Amyloid Formation Through Complementary Approaches
  1290. Early Events in the Onset of Type II Diabetes: Effects of Aggregated Amylin (IAPP) on the Islet Proteome and Metabolic Pathways
  1291. Author Correction: Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model
  1292. Acute Phase Proteins, Immunoglobulins and Cytokines Responses to Amylin Injection in Wister Rats*“Mohamed Mohamed Soliman,“AffDesoky Abdel-Magied’ …
  1293. Dissecting the Role of Amylin Receptor in Alzheimer’s Disease
  1294. AMYLIN RECEPTOR EXPRESSION IN THE MESOCORTICOLIMBIC SYSTEM
  1295. Human Amylin in the Presence of SARS-COV-2 Protein Fragments (preprint)
  1296. Therapeutic potential of an old friend-the dichotomy of amylin in physiology and pathophysiology
  1297. pH Dependence of Amylin Fibrillization
  1298. The role of amylin receptor components in body weight and food intake control in obese knockout mouse models
  1299. Baseline blood amylin levels predict longitudinal cognitive decline in participants at risk for or with mild cognitive impairment and dementia
  1300. The pH-Dependence of Amylin Fibrillization
  1301. 92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial
  1302. Role of Amylin in Obesity
  1303. San Diego survives Amylin shock
  1304. Characterization of the oligomeric forms of human amylin
  1305. Intrinsically disordered proteins (IDP) and metal ions: the case of amylin (HiAPP)
  1306. Amylin, CGRP and the AMY1 receptor: Localisation in the trigeminal ganglia and receptor regulation
  1307. Amylin and its effects on glucose homeostasis.
  1308. In Vivo Downregulation Of Pancreatic Amylin In Diabetic Mice Improves Recognition Memory
  1309. DURAL AMYLIN AND CGRP LEAD TO DIFFERENTIAL SEX-SPECIFIC RESPONSES CONTINGENT ON OVARIAN HORMONES IN RODENT MIGRAINE …
  1310. Amylin under examination. Fibrillogenic potential of the troublesome molecule
  1311. The role of amylin in type 2 diabetes
  1312. The gut-brain axis and alcohol-mediated behaviours: the amylin story
  1313. Synthesis and aggregation dynamics of amylin.
  1314. The role of amylin in Alzheimer’s disease
  1315. Determining the effect of trace elements (Lead and Zinc) on amylin Amyloidogenesis in vitro
  1316. Cerebrovascular accumulation of amyloid‐forming amylin secreted from the pancreas induces brain hypoxia
  1317. Survey of CNS Expression of the Amylin Receptor in Health and Metabolic Disease: Potential Relevance to Alzheimer’s Disease
  1318. … , protofibrils, lipoproteins, and transmembrane channels formed by amyloid beta (Alzheimer’s disease), synucleins (Parkinson’s disease), and amylin (type 2 diabetes)
  1319. Abstract WP247: Amylin, A Diabetes-associated Amyloid-forming Peptide, Accumulates In Thrombi And On Red Blood Cells-A New Biomarker For Stroke?
  1320. Aggregation kinetics of amylin and its optical and electrochemical properties
  1321. Amylin (hIAPP) Aggregates on the Membrane
  1322. Correlation of Serum Amylin Level to Polycystic Ovarian Syndrome.
  1323. In vivo downregulation of pancreatic amylin improves brain function and reduces brain β amyloid pathology in APP/PS1 mice
  1324. Amylin-mediated regulation of LRP1 by miR-103/107 induces cerebral microvascular dysfunction and impairs β-amyloid efflux
  1325. Amylin Inhibits the Feeding of the Siberian Sturgeon
  1326. Characterization of the Amyloidogenic Peptides Amylin & PAP248-286
  1327. ROLE OF PANCREATIC AMYLIN IN ALZHEIMER’S AND BRAIN MICROVASCULAR PATHOLOGIES
  1328. Amylin‐mediated regulation of LRP1 by miR‐103/107 impairs β‐amyloid efflux
  1329. Computational modelling of graphene oxide and amyloidogenic protein amylin
  1330. Phenotypic characterisation of human amylin transgenic mice: altered hormone signalling in the brain underlying obesity and insulin resistance
  1331. Insight into the Metal Binding Sites in Amylin Aggregates
  1332. Mechanisms of Metabolic Hormone Amylin Action on Alzheimer’s Disease Pathogenesis
  1333. Research Article Charge-Based Inhibitors of Amylin Fibrillization and Toxicity
  1334. Identification of Key Interactions in the Initial Self-Assembly of Amylin in a Membrane Environment
  1335. Amylin challenge test and its correlation with brain imaging for Alzheimer’s disease
  1336. Observation of Structural Growth of Fibrils of Amylin Protein
  1337. Serum Amylin Indicates Hypertriglyceridemia in Pre-diabetics
  1338. Evaluating the folding variations in human amylin peptid in the presence of Lead and Selenium
  1339. Affinity Enhancers for Peptide Ligand Binding to the Extracellular Domain of the Amylin Receptor 2
  1340. The role of amylin in the development of diabetic osteopathy
  1341. Combined GLP1 Agonist and Amylin Analogue for Severe Obesity in a Patient with Type 1 DM
  1342. Amylin Interacts with Aβ and May Accelerate the Development of Dementia
  1343. Early Detection of Amylin Aggregation with a Miniature Optical-Fiber Based Sensor
  1344. Copper (II) complexes of rat amylin fragments (360 views)
  1345. Molecular Switches Regulating Assembly Transitions of Biological Molecules: Tubulin, Amylin and Lipids.
  1346. Biophysical perspectives of amyloid-β and amylin induced modulations in its optical and electrical properties
  1347. Presence of UCP2 and Amylin in human Alzheimer’s disease brains
  1348. The effects of systemic administration of amylin on the pancreas of laying hens
  1349. The effects of systemic administration of amylin on the pancreas of laying hens.
  1350. Amylin Detection with a Miniature Optical-Fiber Based Sensor
  1351. Investigating the Phenotype of Amylin Receptor-expressing Cells in the Ventral Tegmental Area
  1352. The Pathophysiological Mechanisms of Human Amylin Induced Stress in Pancreatic Cells
  1353. Elucidating the Mechanism of Human Amylin Trafficking in the Pancreatic β Cells
  1354. Amylin’s Role in Nociception: Study in Amylin KO Mice
  1355. Molecular Dynamics of Amylin Amyloid Single Beta-Sheet
  1356. GM‐CSF reduces amylin amyloid and prevents pancreatic cell death in the hIAPP mouse model of Type 2 diabetes mellitus, a known risk factor for Alzheimer’s …
  1357. Of Mice and Men: Translational Research on Amylin Agonism
  1358. Structure-function analysis of calcitonin and amylin receptors
  1359. Novel, Selective Amylin Agonists as Therapeutic Tools to Treat Diabetes
  1360. Molecular Dynamics Simulation Study on the Molecular Structures of the Amylin Fibril Models
  1361. Molecular Structure, Cytotoxicity and Inhibitive Factors of Human Amylin
  1362. Amylin Structure, Aggregation and Pancreatic β Cell Toxicity
  1363. Identifying a new migraine-relevant receptor: potential paracrine interaction between calcitonin gene-related peptide and the amylin 1 receptor in the parabrachial …
  1364. Construction of human phage antibody library and screening for human monoclonal antibodies of amylin
  1365. INVESTIGATING EFFECTS OF HUMAN AMYLIN AND H202 ON AMYLOID PRECURSOR PEPTIDE (APP) PROCESSING
  1366. Effect of amylin on the expression of steroidogenic acute regulatory protein in mouse brain.
  1367. Effect of Eighteen Weeks Endurance Training and High-Fat Diet on Amylin Plasma Levels of Male Wistar Rats
  1368. Description and potential role in rodents’ maternal care of amylin expressed in the central nervous system
  1369. Unraveling the Molecular Mechanisms of Human Amylin Binding, Turnover and Toxicity in Pancreatic Cells
  1370. Chronic central administration of amylin decreases fat mass but does not modify body weight
  1371. Developing peptide-based inhibitors of amylin aggregation as a novel treatment for type 2 diabetes
  1372. Mutations and Seeding of Amylin Fibril-Like Oligomers
  1373. Investigating the Interactions between Aβ and Amylin: Insight into the Link between Alzheimer’s and Type II Diabetes
  1374. Inhibition of Human Amylin Amyloidogenesis by Human Amylin-Fragment Peptides: Exploring the Effects of Serine Residues and Oligomerization upon Inhibitory …
  1375. Orientations of Residues along the β-Arch of Self-Assembled Amylin Fibril-Like Structures Lead to Polymorphism
  1376. Supplementary Information for ‘Characterizing the Assembly Behaviors of Human Amylin: A Perspective Derived from C-terminal Variants’
  1377. Insights into amylin aggregation by 2D IR spectroscopy
  1378. Correction to “The Fluorescent Dye 1, 6-Diphenyl-1, 3, 5-hexatriene Binds to Amyloid Fibrils Formed by Human Amylin and Provides a New Probe of Amylin Amyloid …
  1379. The effects of vitamin D supplementation on endogen amylin hormone, hormonal and biochemical parameters, and insulin resistance in type-2 diabetic patients with …
  1380. Homology models of the extracellular domains of the calcitonin and amylin receptors, with or without bound amylin and CGRP
  1381. Molecular Mechanisms of the Bindings between Non-Amyloid β Component Oligomers and Amylin Oligomers
  1382. Amylin under examination. Fibrillogenic polypeptide of pancreatic amyloid
  1383. 1993-P: Deconstruction of the Role of the Amylin and Calcitonin Receptors in the Regulation of Body Weight and Glucose Tolerance
  1384. Over-expression of human amylin in transgenic mice as a model for the pathogenesis of gestational diabetes
  1385. Regulation of amyloid‐beta pathology by CNS amylin receptors in APP/PS1 mice: Development of new models and analysis methods/amyloid/Abeta
  1386. Effect of Peptide Conjugates of Carboxylic Acids to the Aggregation of Amylin
  1387. Microhemorrhages in Myocardium and Kidneys Provoked by Amylin-Loaded Erythrocytes
  1388. Aggregation Induced Conformation Changes Determine Amylin Membrane Affinity
  1389. EQUILIBRIUM INVESTIGATIONS OF METAL ION COMPLEXES OF AMYLIN HORMONE FRAGMENTS AND ITS MUTANTS
  1390. Impact of the inhibition of UCP2 on the activity and presence of Amylin in RIN‐5F cells
  1391. Low blood amylin delays Alzheimer’s pathology by modulating brain hypoxia and amyloid composition: A study in humans and rats: Biomarkers (non‐neuroimaging) …
  1392. Lipid membrane disruption by amylin in type II diabetes mellitus: Effect of head group loss
  1393. Exploration of Non-Specific Peptide Inhibitors of Amylin Aggregation in Type-2 Diabetes
  1394. Metabolic and neurogenic effects of amylin in the rodent Area postrema
  1395. 211-OR: Dual Amylin and Calcitonin Receptor Agonists Increase Mitochondrial Respiratory Capacity in Adipose Tissues of Obese Rat
  1396. Diabetes Mellitus Drug Discovery: Insights into Targeting Feline and Human Amylin with Small Molecules
  1397. Molecular Simulations Indicate Marked Differences in the Structure of Amylin Mutants, Correlated with Known Aggregation Propensity
  1398. Probing Ion Channel Activity of Human Islet Amyloid Polypeptide (Amylin)
  1399. ThT and Capillary Electrophoresis to Monitor the Effects of Solutions Conditions on Amylin Aggregation
  1400. Intrathecal amylin and salmon calcitonin affect formalin induced c-fos expression in the spinal cord of rats
  1401. Structural Insights to Toxic Amylin Oligomers from 2D IR Spectroscopy
  1402. In Silico Molecular Docking of Fisetin with the Amyloidogenic Peptides Human Amylin and Aβ42
  1403. Characterising Interactions Between Amyloid-beta 42 and Amylin Peptide Heterodimers: A Molecular Simulation Approach
  1404. Investigating the role of de novo designed peptides in ameliorating amylin aggregation and β-cell toxicity in Type 2 Diabetes (T2D)
  1405. Amylin mediates brainstem control of heart rate in the diving reflex
  1406. Amylin and pramlintide modulate γ-secretase activity and APP processing in lipid rafts
  1407. The effects of amylin on the clearance and aggregation of amyloid beta in BV-2 microglia cell culture
  1408. Abstract W P252: Amylin Vasculopathy, a Novel Mechanism of Cerebrovascular Injury and Neurologic Deficits in Diabetes
  1409. High-Resolution Imaging of Amylin Aggregation and Internalization in Pancreatic Cells: Implications in Health and Disease
  1410. Involvement of the histaminergic system in amylin and leptin action-a study with H1rKO mice
  1411. The effects of astragalus combined with metformin on insulin resistance and plasma amylin level in newly diagnosed type 2 diabetic patients
  1412. In silico folding and aggregation study of human amylin, an amyloidosis protein
  1413. Amylin under examination. Fibrillation–cytotoxic pancreatic polypeptide aggregation
  1414. Amylin-induced microglial IL-6 production enhances ventromedial hypothalamic leptin signaling
  1415. Deamidation Accelerates Amyloid Formation and Alters Amylin Fiber Structure
  1416. Correction: Complex formation of nickel (ii) and zinc (ii) ions with peptide fragments of rat amylin
  1417. Pre-Diabetes Promotes Buildup of Amylin in the Heart That Alters Cardiac Function by Remodeling the Myocytes
  1418. A Single Pseudoproline and Microwave Solid Phase Peptide Synthesis Facilitates an Efficient Synthesis of Human Amylin 1â [euro]” 37
  1419. Increased toxicity of amylin (Islet Amyloid Polypeptide) in beta cells induced by photochemical internalization
  1420. Amylin Peptide: An Association with Feed Intolerance in Preterm Neonates and Infants of Diabetic Mothers
  1421. 840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats
  1422. 861-P: The Effect of Dual Amylin and Calcitonin Receptor Agonist Treatment on Spatial Memory in Rat Models of Metabolic Syndrome
  1423. Computational Study of Human-Amylin Induced Calcium Dysregulation in Cardiac Myocytes Characteristic of Pre-Diabetes
  1424. Comparing Solution Structures of Amylin and CGRP by Nanosecond Laser-Pump Spectroscopy and Atomistic Simulations
  1425. Amylin dual action: a second gluco regulatory β-cell hormone, treatment and cause for the diabetes
  1426. Amylin Amyloid Inhibition by Flavonoid Baicalein: Key Roles of Its Vicinal Dihydroxyl Groups of the Catechol Moiety
  1427. Amyloid Accelerators: Small Molecules that Accelerate Amyloid Formation by Amylin
  1428. Expression and characterization of the human amylin receptor AMY3 in the mammalian cell-line RK13 (rabbit kidney cells) as a cellular model for Amyloid beta …
  1429. Diet-derived protein and amino acids attenuate the responsiveness of the area postrema to the anorectic hormone amylin in male rats
  1430. The study of the formation of oligomers and amyloid plaques from Amylin by capillary electrophoresis and fluorescent microchip electrophoresis
  1431. 213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats
  1432. Circulating Amylin Amyloid Oligomers Accumulate in the Heart and Induce Cardiomyocyte Dysfunction in a Rat Model of Type-2 Diabetes
  1433. Targeting a metabolic OA in vivo model by a novel dual amylin calcitonin receptor agonist, KBP-056
  1434. A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ1–42, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing …
  1435. Back Picture: Ion‐Transfer Electrochemistry of Rat Amylin at the Water–Organogel Microinterface Array and Its Selective Detection in a Protein Mixture (Chem. Asian J …
  1436. 1406-P: ZP8396, a Novel Amylin Analogue, Induces Weight Loss in DIO Rats with a Formulation Space at Physiological pH
  1437. Ginger Essential Oil and Citral Ameliorate Atherosclerosis Via Modulating TMAO and Gut Microbiota in ApoE −/− Mice Fed on Gubra Amylin NASH Diet with ʟ …
  1438. Early postnatal amylin treatment enhances hypothalamic leptin signaling and 1 neural development in the selectively bred diet-induced obese rat. 2
  1439. Modulation of Prepulse Inhibition and Ingestive Behavior by Nucleus Accumbens AMY1 Amylin Receptors
  1440. Influence Of Specific Hsc70 Domains On Fibril Formation Of Human Amylin Involved In Type 2 Diabetes: Importance Of The C-terminal Lid
  1441. Over-expression of Human Amylin Leads to Oligomerization and beta-cell Dysfunction Associated with Mitochondrial Uncoupling, Activation of c-Jun and Decrease …
  1442. Localization of amylin-like immunoreactivity in melanocyte-stimulating hormone-containing cells of the pars intermedia but not those of the pars distalis in the axolotl …
  1443. 1393: AN AMYLOIDOGENIC HEXAPEPTIDE, AMYLIN, ATTENUATES INFLAMMATION AND ACUTE LUNG INJURY IN MURINE SEPSIS
  1444. Healthy pancreatic b-cells secrete the hormones insulin and amylin in a fixed ratio. Both hormones are lacking in type 1 diabetes, and postprandial glucose …
  1445. Amylin and preptin regulate glucose homeostasis in infertile women with polycystic ovary syndrome and poor responders undergoing IVF/ICSI
  1446. 1829-P: Aggravating Liver Lipid Accumulation and Fibrosis in Nonalcoholic Steatohepatitis Model of MS-NASH Mice by a Modified Amylin Diet
  1447. 1306-P: In Vivo Downregulation of Pancreatic Amylin in Diabetic Mice Improves Recognition Memory
  1448. P3-091 PLASMA AMYLIN LEVELS ARE ASSOCIATED WITH BRAIN STRUCTURE AMONG INDIVIDUALS WITH TYPE-2 DIABETES
  1449. 823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in …
  1450. 824-P: Dual Amylin and Calcitonin Receptor Agonists Improve Insulin Sensitivity and Increase Tissue-Specific Glucose Uptake Independent of Weight Loss
  1451. PS 0121; Cardiology: Is Serum Amylin Level Associated with Myocardial Function in Type 2 Diabetes Mellitus Patient without Cardiac Diseases?
  1452. Plasma Ghrelin and GLP-1, but not Leptin or Amylin, Respond to a Psychosocial Stressor in Humans
  1453. 2035-P: Treatment with a Dual Amylin and Calcitonin Receptor Agonist Improves Metabolic Health in a Rat Model of Elderly Menopausal Women
  1454. 750: ENDOGENOUS GHRELIN, AMYLIN AND GLUCAGON-LIKE PEPTIDE-1 AND THEIR ASSOCIATIONS WITH GASTRIC EMPTYING IN THE CRITICALLY ILL
  1455. Design, synthesis and testing of a novel fluorescent probe for the staining of amyloid fibrils of Aβ1-42 peptide, α-synuclein and amylin and for the detection of amyloid …
Related Posts

Thrombolytics (Plant Based)

Organotins

BCL-2

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping